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Background: Acute respiratory failure (ARF) is the most common type of organ 
failure leading to the need for intensive care. It is often secondary to acute lung 
injury (ALI) and its more severe form, acute respiratory distress syndrome (ARDS). 
These disorders are characterised by inflammatory reaction and tissue damage. 
After the inflammatory reaction ceases, it is typically followed by a repair process 
and restored organ function. In some cases, inflammation continues and leads 
to an overwhelming repair process with ongoing fibrosis, accompanied by organ 
dysfunction and eventually a loss of function. 
ARF, and especially ALI and ARDS, cause increased morbidity and a need for 
intensive care. Mortality rates remain high (up to 40%) despite extensive research 
efforts and increased caution in patient care. Mechanical ventilation, although 
a lifesaving treatment for ARF, can cause injury to the lungs and amplify the 
inflammatory process; however the use of a lung protective ventilatory strategy is 
known to improve the outcome in ALI and ARDS. 
Measuring the magnitude of the inflammation, and the repair process, early 
in the course of disease, would theoretically offer information concerning the 
outcome. Early identification of patients whose disease process is likely to proceed 
unfavourably, would help clinicians to optimise their treatment and target novel 
therapies reasonably. Different biomarkers have been studied in order to understand 
the process of lung injury, find new therapies, and predict outcome. 
The aim of this study was to evaluate the epidemiology of ARF, its treatment, 
and outcome in Finland, with special interest in biomarkers, and their value in the 
prediction of mortality.
Patients and methods: Altogether, 958 patients were prospectively included in 
this study during an eight week period in 2007. The patient cohort comprised adult 
patients treated in 25 intensive care units with invasive or non-invasive ventilatory 
support for more than six hours. The whole cohort was studied in order to investigate 
the epidemiology, treatment methods used, and the outcome of ARF in Finland 
(Study I). Concentrations of aminoterminal pro-brain natriuretic peptide (NT-pro-
BNP) were assessed in 602 patients (Study II), and plasma cell-free DNA in 580 
patients (Study III), to evaluate their value as prognostic markers in ARF. Finally, in 
68 patients, procollagen type I and III aminoterminal propeptides (PINP, PIIINP) 
were studied as markers of collagen synthesis and collagen type I cross-linked 
telopeptides (ICTP) as a marker of collagen I degradation. Their concentrations in 
longitudinal serum samples were measured in order to evaluate their evolution in 
10
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ARF patients with and without multiple organ dysfunction (Study IV).
Main results: Of all 2473 patients admitted to intensive care units, 958 (39%) were 
treated with ventilatory support for more than six hours. The estimated incidence of 
ARF treated in the ICUs over this eight-week period was 149.5 / 100 000 per year. 
Median tidal volume per predicted body weight was higher than recommended, 
median 8.7 ml/kg. Overall mortality at 90 days was 31%.
Both plasma NT-pro-BNP and cell-free DNA concentrations were highly 
increased in ARF patients, and levels were higher in 90-day non-survivors than 
survivors. NT-pro-BNP values were higher in patients with cardiac condition, and 
with renal dysfunction. Plasma NT-pro-BNP was a moderate predictor of 90-day 
mortality. Plasma cell-free DNA levels were higher in non-operative patients with 
infection than without infection. Baseline values of plasma DNA were independent 
predictors of 90-day mortality, but the discriminative power was poor. 
NT-pro-BNP and plasma cell-free DNA remained independent predictors for 
90-day mortality in logistic regression analysis including both biomarkers. The 
mortality was highest in those patients, in whom both biomarkers were over their 
separate cut-off values.
PIIINP levels increased over time in ARF patients with prolonged hospitalization. 
PINP levels also increased, but the degradation exceeded the synthesis during first 
week of ARF. The markers of collagen metabolism showed recovery back to baseline 
at day 21. None of the markers of collagen metabolism did associate with multiple 
organ dysfunction. 
Conclusions: The estimated incidence of ARF treated in the ICU was 149.5 / 100 
000 per year in Finland. Ventilatory support for more than six hours was used in 
39% of all ICU patients. The 90-day mortality in ARF was 31%. Lung protective 
ventilatory strategy was adapted moderately. Plasma NT-pro-BNP and cell-free 
DNA were commonly high in ARF patients, and both were independent predictors 
of 90-day mortality. However, plasma NT-pro-BNP concentrations were affected 
by renal failure, and the sensitivity and specificity of plasma cell-free DNA values 
were poor. Combined use of these biomarkers, however, may increase their clinical 
value in mortality prediction. The degradation of collagen type I and synthesis of 
collagen type III increased during the first week in surviving patients. Collagen 
metabolism approached normal levels at three weeks. 
Keywords: Acute respiratory failure, intensive care, mortality, outcome, N-terminal-
pro-brain natriuretic peptide, plasma cell-free DNA, collagen, procollagen propeptide
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1 INTRODUCTION 
Acute respiratory failure (ARF) is the most common organ failure reported in 
intensive care unit patients (Flaatten et al. 2003). In fact, according to most reports, 
45-60% of all patients admitted to intensive care units require respiratory support 
(Demoule et al. 2006, Roupie et al. 1999, Vincent et al. 2002). Since almost all 
diseases and organ dysfunctions can lead to insufficient pulmonary ventilation, 
pulmonary oxygenation, or both, triggers for ARF are very heterogeneous. They 
can also initiate an inflammatory reaction that leads to acute lung injury (ALI) or 
its more severe form, acute respiratory distress syndrome (ARDS). ALI and ARDS 
are important precursors of ARF and share common pathophysiological features. 
They are characterised by inflammatory reaction and tissue damage, histologically 
depicted as diffuse alveolar damage (DAD), resulting in a clinical picture of 
deteriorating oxygenation and/or ventilation. The inflammatory reaction often 
ceases, and is followed by repair process and restored organ function. Nonetheless, 
inflammation does continue in some cases, where it leads to an overwhelmed repair 
process with ongoing fibrosis accompanied by organ dysfunction and, in the worst-
case scenario, loss of function.
Introducing ventilatory support in ARF can be life saving, assuming that the 
disorder leading to respiratory failure is temporary and can be treated. Ventilatory 
support, however, is known to be potentially injurious. Since the first landmark 
studies (Dreyfuss et al. 1985, Webb et al. 1974), numerous other experimental 
studies have shown that lung injury can ensue in previously healthy lungs after 
implementing injurious ventilatory settings. More recent clinical studies have also 
supported these findings (Gajic et al. 2005, Pinheiro de Oliveira et al. 2010). A 
lung protective ventilatory strategy for ALI and ARDS patients, aiming to avoid 
overdistension and cyclic opening and closing of alveoli, has been established a 
decade ago, based on a large multicentre study (ARDSNet 2000). Mortality has 
been suggested to have decreased to some extent, but still remains high at around 
40% (Esteban et al. 2008, Zambon et al. 2008).
A detailed understanding of ARF is lacking, given that typically non-homogeneous 
studies of very different patient materials are reported, due to lack of standard 
definition. Instead, the most severe forms of ARF, acute lung injury (ALI) and 
acute respiratory distress syndrome (ARDS), have been the research target of 
interest over the last decades. ARDS as a clinical syndrome was first described in 
1967 by Ashbaugh and colleagues (Ashbaugh et al. 1967). Standard definitions for 
ALI and ARDS were formulated by American-European Consensus Conference 
(AECC) in 1994 (Bernard et al. 1994). Due to the lack of a standard definition, the 
12
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need for mechanical ventilation has been commonly used as a definition of ARF 
in epidemiological studies.
Preventing ALI is a desirable goal, since it causes increased morbidity and 
mortality, and its treatment is expensive. Early identification of those patients who 
are at a high risk of developing severe lung injury would help clinicians to optimise 
their treatment and to target novel therapies. In most cases, the development of 
severe lung injury is multifactorial, including genetic predisposition. Thus, in order 
to prevent ALI, it is essential to focus on a large and unselected patient population 
with existing risk factors for ALI. Patients treated with ventilatory support represent 
a plausible study population, since after the original injurious incident, ventilatory 
treatment can be considered a second hit, increasing the risk of ALI. Due to the 
inflammatory nature of ALI, encompassing numerous elements of inflammatory 
and coagulation cascades, a myriad of possible biomarkers for ALI exist. Biomarker 
studies have not only increased the knowledge of pathophysiological pathways, 
but also yielded some biomarkers that have shown promise in the diagnostics and 
outcome prediction for ALI and ARDS.    
The epidemiology of ARF and its treatment in Finland have not been studied 
previously, thus a clear opening for a new investigation is evident. Furthermore, 
measuring the magnitude of the inflammation and the repair process would be 
advantageous in theory. Early identification of those patients, whose disease process 
is likely to proceed unfavourably, would help clinicians to optimise their treatment 
and target novel therapies reasonably. In addition, it would be of great interest to 
find new and individual tools for prognostic purposes. The aim of this thesis was to 
study the epidemiology of ARF, its treatment, and outcome in Finland, with special 
interest in biomarkers, and their value in the prediction of mortality.
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2 REVIEW OF LITERATURE 
2.1. the epIDemIOlOgy OF arF, alI aND arDS
2.1.1. DeFINItIONS 
2.1.1.1. ARF
Respiratory failure may be described as an incapability of the respiratory system 
to maintain sufficient function with regard to demands. The respiratory system 
has two functions, oxygenation of blood and elimination of carbon dioxide. The 
failure of either or both of these functions results in hypoxemia and/or respiratory 
acidosis (Roussos et al. 2003). If the onset of the failure is acute, the compensatory 
mechanisms do not have time to work and a life threatening situation ensues. 
 Numerous illnesses and pathological states can result in acute respiratory 
failure. Primary pulmonary diseases may directly affect gas exchange, the control 
of breathing may be disabled by central nervous system disease, and systemic 
inflammatory reaction may cause increased oxygen consumption or increased 
production of carbon dioxide resulting in increased work of breathing and respiratory 
muscle fatigue. This miscellaneous background and the symptom-like nature of ARF 
most probably is one reason why a standard definition is lacking. 
 Most studies have only included patients with ALI or ARDS, but these syndromes 
cover a minority of ARF patients. In a Nordic multicentre study, where ARF was 
defined as invasive mechanical ventilation for more than 24 hours, ALI or ARDS 
definitions were fulfilled in 287 (23%) of 1231 ARF patients (Luhr et al. 1999), in 
agreement with proportions reported by others (Villar et al. 2007). Even smaller 
proportions of ALI patients have been found, when mechanically ventilated 
patients have been evaluated (Esteban et al. 2008, Roupie et al. 1999). Widely 
differing definitions of ARF have been used, some including criteria for oxygenation 
(Flaatten et al. 2003, Vincent et al. 2002), and some demanding invasive ventilation 
(Lewandowski et al. 1995, Luhr et al. 1999).
 The use of variable inclusion criteria has resulted in wide range of study results. 
Table 1 presents epidemiological studies with different patient populations included, 
and also the proportions of ALI/ARDS from study patients.
14
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AECC, American-European Consensus Conference; ALI, Acute lung injury; ARDS, Acute respiratory distress 
syndrome; ARF, Acute respiratory failure; ICD-9-CM, The International Classification of Diseases, Ninth Revision, 
Clinical Modification; ICU, Intensive care unit; LIS, Lung injury score; MV, Mechanical ventilation
table 1. epidemiological studies of arF or alI/arDS
Study Setting IcU 
admissions
Study patients
* Inclusion criteria entitled as arF 
patients alI/arDS 
of study patients
Incidence 
/100 000
hospital mortality comment
lewandovski 1995 72 ICUs in Berlin
1991, 8 weeks
Prospective
NA * Intubation 
+ MV ≥ 24 h (≥14 years)
508 17 (3.6%) Severe lung injury 
(LIS > 2.5)
ARF 88.6
Severe lung 
injury 3.0
42.7% (ICU) 
59% ARDS (LIS>2.5)
Severe lung injury defined 
as LIS > 2.5
roupie 1999 36 French ICUs
1996, 14 days
Prospective
976
(424 with MV)
PaO2/FiO2 < 300 mmHg + MV + acute 
unset (NIV included) 
213 67 ARDS 
(31.5% of study patients and 
15.8% of MV patients) 
NA 40% (28 d) 
60 % ARDS
49% of patients admitted 
from wards to ICU
luhr 1999 132 ICUs in 3 Nordic countries 
1997, 8 weeks 
Prospective
13 346 * Intubation + MV ≥ 24 h 1231  287 (23%) ARF 77.6
ALI 17.9
ARDS 13.5
ARF 41% *
ALI (not ARDS) 42.2% 
ARDS 41.2%
* 90-day mortality
Behrendt 2000 Register data analysis,  
1994, 1 year
Retrospective
NA * ICD-9-CM code for acute respiratory 
distress or failure + MV  (>5 years)
61 223 NA ARF 137.1 35.9% Based on hospital discharge 
data
vincent 2002 40 ICUs in 16 countries, 
1995, 1 month
Prospective
1449 * PaO2/FiO2 < 200 mmHg + MV 
(≥12 years)
(NIV included)
458 at adm. +
352 at ICU 
NA NA 34% 23% postoperative patients
Bersten 2002 21 adult ICUs in 3 Australian 
states
1999, 8 weeks
Prospective
1977 ALI/ARDS 
(AECC criteria)
(NA) 168 (8.5% ) ALI/ARDS
148 (7.5%) ARDS
ALI 34
ARDS 28
32% overall (28 d)
15% ALI, not ARDS
34% ARDS 
Barotrauma in pulmonary 
ALI 16%, in non-pulm. 1.5%, 
p<0.001 
esteban 2002 361 ICUs in 20 countries,
1998, 28 days
Prospective
15 757 MV > 12 h 
(NIV included) 
5183 231 (4.5%) NA 39.2% PaO2/FiO2 independent 
predictor of death
Flaatten 2003 One ICU in Norway,  
2000-2002, 2.5 years
Prospective
832 * SOFA 3 or 4 at least on 2 days 
(>16 years)
(NIV included)
392 at adm. +
137 at ICU 
NA NA 32.9% 
14.7% single organ ARF
Gradual increase in 
mortality with number of 
failing organs
goss 2003 20 hospitals in United States
1996-1999
Prospective
NA ALI/ARDS 
(AECC criteria)
(NA) 7455 ALI/ARDS 64 NA Based on screened 
patients in ARDSNet study 
(ARDSNet 2000)
Brun-Buisson 2003 78 ICUs in 10 European 
countries
1999, 2 months
Prospective
6522 ICU stay > 24 h or ALI/ARDS at admission 2768 463 (16.1%) NA 49.4% ALI, not ARDS
57.9% ARDS
Large variation in ARDS 
prevalence in different 
centres
rubenfeld 2005 21 hospitals in one county in 
USA
1999-2000, 12 months,
Prospective
NA
(6235 
admissions 
with MV)
MV > 24 h 
 (> 6 months of age)
4251 1113 (26%) ALI
828 (19%) ARDS
ALI 78.9
ARDS 58.7
38.5% ALI, including 
ARDS
41.1% ARDS
Only 34% discharged to 
home 
esteban 2008 349 ICUs in 23 countries
2004, 1 month
Prospective
19 505 MV > 12 h 
(NIV included)
4968 198 (4%) ARDS NA 37% all patients 
63% ARDS
A follow-up study of a 
previous epidemiological 
study (Esteban et al. 2002)
the Irish critical care 
trials groups 2008
14 ICUs in Ireland, 
10 weeks
Prospective
1029 
(728 with MV)
ALI/ARDS 
(AECC criteria)
196 196 ALI/ARDS (19% of 
admissions and 27% of MV 
patients)
NA 32% (ICU) PaO2/FiO2 independent 
predictor of death
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2.1.1.2. ALI and ARDS 
Whilst the first descriptions of lung oedema appearing without heart failure were 
written in the early 1800’s, ARDS was first described by Ashbaugh and colleagues in 
1967 (Ashbaugh et al. 1967). They described twelve patients with clinical symptoms 
of severe dyspnoea and cyanosis associated with diffuse alveolar infiltrates seen in the 
chest x-ray; their symptoms were resistant to usual respiratory therapy approaches. 
Two decades later, an attempt to define lung injury was made by Murray and 
colleagues (Murray et al. 1988). Their definition included three parts: time frame 
(acute or chronic), severity of the lung injury, and the cause of the lung injury. The 
severity of the lung injury was assessed by lung injury score (LIS), which included the 
level of positive end expiratory pressure (PEEP) and respiratory system compliance, 
in addition to the severity of the oxygenation problem, and the number of quadrants 
affected in the chest x-ray. This definition has been used in some interventional 
studies (Peek et al. 2009), but has not been adopted widely in epidemiological 
studies as a diagnostic criteria. The lung injury score, however, has been favoured 
as a quantitative index of ALI severity.
 In 1994, the AECC formulated diagnostic criteria for ALI and ARDS (Bernard 
et al. 1994), presented in Table 2. The purpose was to standardise the patient 
populations included in clinical trials, since the definitions, thus patients and results, 
in earlier studies had varied widely. 
table 2. the diagnostic criteria of alI and arDS according to aecc (Bernard et al. 1994).
Acute onset
Bilateral infiltrates in chest x-ray
Absence of left atrial hypertension 
    (PCWP < 18 cmH2O or clinical exclusion)
PaO2/FiO2  ≤ 300 mmHg (≤ 40 kPa) for ALI and 
                 ≤ 200 mmHg (≤ 27 kPa) for ARDS 
AECC, American-European Consensus Conference; ALI, Acute lung injury; ARDS, Acute respiratory 
distress syndrome; kPa, kilopascal; PCWP, pulmonary capillary wedge pressure 
These criteria have been criticised for many reasons. First, ventilatory settings 
are not taken into account, although they are known to have a significant effect 
on oxygenation and, thus, the fulfilment of the criteria. In a study by Villar and 
colleagues, 170 patients met ARDS criteria at baseline (Villar et al. 2007). After 
adjustments in the PEEP level and in the inspired oxygen fraction, only 99 (52%) 
fulfilled ARDS criteria, while 55 patients had shifted to the group fulfilling ALI 
criteria and 16 patients did not meet the ALI/ARDS criteria at all. Second, the ratio 
of arterial oxygen pressure and the fraction of inspired oxygen (PaO2/FiO2 –ratio), 
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which is used as a measure of oxygenation in AECC–criteria, can be manipulated 
by simply changing the inspired oxygen fraction (Aboab et al. 2006, Karbing et 
al. 2007). 
 Additionally, AECC criteria do not necessarily correlate with patients’ clinical 
status. In a recent study, 715 patients treated in respiratory wards were evaluated for 
ALI/ARDS criteria (Quartin et al. 2009). Of these 715, 474 (66%) had acute infiltrates 
in their chest x-ray, 62 (9%) fulfilled the criteria for ALI, and 15 (2%) for ARDS. 
Patients with ALI criteria displayed a 90-day mortality of only 12%, in contrast to a 
10% mortality rate for patients not fulfilling the criteria. This result suggests that the 
criteria currently used to evaluate for ALI/ARDS are neither sensitive nor specific 
enough to reliably find patients with acute lung injury. Indeed, in an autopsy study 
of 133 patients who had been diagnosed to have ARDS, the characteristic histological 
picture of DAD, a gold standard in the diagnosis of ARDS, was seen only in 119 
patients (Esteban et al. 2004). The remaining 14 patients with a clinical diagnosis 
of ARDS were diagnosed to have suffered from pneumonia, alveolar haemorrhage, 
pulmonary oedema or embolism, and fibrosis due to chemotherapy. Sensitivity and 
specificity were calculated for AECC criteria, and were found to be only moderate, 
with a sensitivity of 75% (95% confidence interval [CI], 66% to 82%) and specificity 
84% (95% CI, 79% to 88%) in all patients. In patients demonstrating clinical risk 
factors, the values remained somewhat lower, both were 75%. In contrast, for 
patients with non-pulmonary risk factors, both sensitivity and specificity were 
higher, signifying the importance of underlying pathophysiology.
 Despite the obvious weaknesses in the criteria used to define ALI, and 
continuing suggestions to refine them (Lewandowski 1999, Rumbak et al. 2009), 
inclusion criteria in practically all studies concerning ALI are based on those 
defined in table 2. 
2.1.2. INcIDeNce 
Due to inconsistencies in its definition, studies concerning ARF and its incidence 
are inconsistent. Given that ALI/ARDS patients are defined as a proportion of 
ARF/MV patients in many studies, the inclusion criteria used for ARF has great 
impact in this estimate (Table 1). The ARF incidence rates reported have ranged 
from 77.6 / 100 000 per year in a Nordic study covering Sweden, Denmark, and 
Iceland (Luhr et al. 1999) to 137.1 / 100 000 per year in a retrospective register 
data analysis (Behrendt 2000). Correspondingly, the incidence numbers for ARDS 
(AECC criteria) have varied from 4.9 / 100 000 per year in a 3-year retrospective 
analysis in one hospital (Valta et al. 1999) to 58.7 and 64 / 100 000 per year in 
more recent studies from the United States (Goss et al. 2003, Rubenfeld et al. 2005). 
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Lower incidences of 1.5 to 3.5 / 100 000 per year have been reported with a more 
strict ARDS definition (Villar et al. 1989) and 3.6 / 100 000 per year with ‘severe 
lung injury’ defined by LIS score (Lewandowski et al. 1995). 
2.1.3. OUtcOme
Large variation is seen in both the clinical outcome of ARF, ALI, and ARDS, and 
their incidence. A crude mortality rate of 35-40% is reported for ARF in most studies 
(Behrendt 2000, Luhr et al. 1999, Roupie et al. 1999), and 30-60% for ALI/ARDS 
(Bersten et al. 2002, Brun-Buisson et al. 2004, Rubenfeld et al. 2005). 
 Whether the mortality of ALI/ARDS has been decreasing over decades is under 
debate, since the results have not been consistent and the interpretations have also 
differed, as reported in two recent systematic reviews (Phua et al. 2009, Zambon et 
al. 2008). Zambon and Vincent analysed ALI/ARDS studies from 1994 (when the 
AECC criteria were published) to 2006, and included 72 studies with more than 
30 patients (Zambon et al. 2008). They found that mortality rates showed wide 
variation from 15% (28-day mortality) to 72% (hospital mortality) between studies, 
the overall mortality being 43%. Mortalities reported in studies varied from ICU 
to 60-day mortality. A constant reduction in the overall and hospital mortalities, 
but not in others, was noticed over time. In another systematic review, 89 studies 
including at least 50 patients with ALI/ARDS, were evaluated (Phua et al. 2009). 
Studies were pooled according to a publishing year, thus were published before or 
after the AECC consensus criteria in 1994 (Bernard et al. 1994), and also according 
to study design, namely observational versus randomized controlled trials (RCT). 
The overall mortality in all studies was 44.3%. Mortality was noticed to decrease 
over time in observational studies conducted before year 1994, however from 1994 
to 2006 no changes in mortality over time were perceived. In the era from 1994 
to 2006, the mortality rate differed significantly according to study design, being 
44% in observational, and 36% in randomized controlled trials (RCT). 
2.1.3.1 Parameters affecting outcome 
Diverse definitions used in earlier studies are partly responsible for variable results, 
but differences in the local treatment protocols, organizational factors, admission 
policies, and also populations may also have had an effect on differing results. 
When the effect of closed versus open ICUs on hospital mortality was evaluated, 
the mortality was significantly lower in ALI patients in the closed ICUs (Treggiari 
et al. 2007). In open ICUs, 31% of the patients were ventilated with tidal volumes 
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known to be injurious (over 12 ml/kg), compared to 10% in closed ICU, which 
may be a plausible explanation for the increased mortality in open ICUs. Another 
study has shown that higher hospital volume, thus the higher number of patients 
treated, is associated with decreased mortality in mechanically ventilated patients 
(Kahn et al. 2006). 
 Predisposing factors for ALI and ARDS also have an impact on the outcome. 
The mortality in ALI/ARDS has been reported to be highest in sepsis induced ALI 
(Brun-Buisson et al. 2004, Doyle et al. 1995). Trauma patients, in contrast, have a 
better prognosis, which is not entirely explained by the baseline characteristics, but 
has been shown to associate with lower levels of biomarkers for both epithelial and 
endothelial injury (Calfee et al. 2007). Two retrospective analyses have suggested 
that race may impact the outcome (Erickson et al. 2009, Moss et al. 2002), 
however another study found no racial difference in trauma patients regarding 
ALI development, its severity, or mortality (Brown et al. 2011). Nonetheless, other 
genetic factors may still have an effect on survival (Marshall et al. 2002)
 The impact of the severity of the oxygenation problem on mortality has varied 
in earlier studies. In a Nordic multicentre study, mortality rates were comparable 
in different groups, where 90-day mortality was 41% for ARF (including ALI 
and ARDS patients), 42% for ALI (not including ARDS), and 41% for ARDS 
patients (Luhr et al. 1999). In another study, the long-term outcome in critically 
ill trauma and sepsis patients did not differ, whether the ARDS was diagnosed or 
not (Davidson et al. 1999). Some other studies, on the other hand, have shown 
significant differences in outcome according to the severity of lung injury (Esteban et 
al. 2002, IrishCriticalCareTrialsGroup 2008, Roupie et al. 1999, Villar et al. 2007). 
Overall, PaO2/FiO2 – ratio on the first day of ALI/ARDS has not been shown to be 
an independent predictor of mortality (Ware 2005).
 Acute respiratory failure is an infrequent cause of death in ARDS patients. A 
landmark study by Montgomery and colleagues, reported that in only 16% of patients 
with ARDS, death was caused by acute respiratory failure (Montgomery et al. 1985). 
In most cases, when occurring after the first days of disease onset, death is related 
to other organ failures, especially to multiple organ failure (Ferring et al. 1997). 
Mortality has been shown to associate more with other organ dysfunctions than 
respiratory failure per se (Flaatten et al. 2003). Flaatten and colleagues reported 
hospital mortality as low as 15% in acute respiratory failure, as a single organ failure, 
however this increased as organ failures compounded. A comparable mortality rate 
of 17% with a single organ ARF has been reported, however patient number with 
ARF as a single organ failure was only 24 (Pettila et al. 2002). In addition, the 
combination of ARF with any other organ failure led to a steep increase in mortality, 
ranging from 51% with circulatory failure, to 75% with hematologic failure. Other 
organ dysfunctions have also independently predicted death in studies on ALI/
ARDS (Brun-Buisson et al. 2004, Doyle et al. 1995).  
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2.2. mechaNISmS OF acUte lUNg INjUry aND aSSOcIateD 
BIOmarkerS
Lung injury may commence with diverse early pathophysiology, caused by either 
direct or indirect mechanisms. These mechanisms each constitute approximately 
half of the cases of ALI/ARDS (Bersten et al. 2002, Luhr et al. 1999, Villar et al. 2007). 
The site of injury is alveolar epithelium in direct pulmonary injury as in aspiration 
and pneumonia, and vascular endothelium in indirect extrapulmonary injury, as 
in sepsis, trauma, massive transfusion. Both situations, or often a combination of 
them, result in increased vascular permeability, interstitial fluid accumulation, and 
inflammatory cell migration in alveolar spaces (Ware et al. 2000). Air spaces flood 
with protein rich oedema fluid, and activated neutrophils and macrophages release 
inflammatory mediators and proteases, which further amplify the inflammatory 
process and injury. Histologically acute lung injury is characterised by DAD (Castro 
2006, Katzenstein et al. 1976). This includes type II alveolar epithelial cell (AEC) 
loss, leading to surfactant deficiency and functional impairment, while destruction 
of type I AECs results in impairment of gas exchange. 
 The inflammatory and regenerative processes take place in the denuded alveolar 
epithelium (Pugin et al. 1999). Epithelium disruption triggers the activation of 
coagulation cascades, leading to a subsequent activation of tissue fibroblasts. 
Myofibroblasts are stimulated, for example by activated transforming growth factor 
(TGF)-β, to secrete procollagens (Scotton et al. 2007) (Figure 1). Excess collagen, in 
turn, is degraded by matrix metalloproteinases (MMPs), as are other extracellular 
matrix structural components, thus MMPs are important in the regulation of tissue 
remodelling. They also participate in the regulation of inflammation and immunity, 
participating in both pro- and anti-inflammatory actions. In fact, proinflammatory 
mediators tumor necrosis factor (TNF)-α and TGF-β have been reported to induce 
the action of MMP-2 and MMP-9 (Han et al. 2001a, Han et al. 2001b).  
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Figure 1. Simplified mechanisms of acute lung injury, drawn by helena Schmidt according to 
draft by marjatta Okkonen.
A, apoptosis; AEC, alveolar epithelial cell; F, fibroblast; ICTP, collagen type I cross-linked 
telopeptides; M, macrophage; MMPs, matrix metalloproteinases; N, neutrophil; PAF, platelet 
activating factor; PAR-1, protease activated receptor-1; TNF-α, tumor necrosis factor- α; TGF-β, 
transforming growth factor-β
 
Although many features of ALI are common to both direct pulmonary and indirect 
extrapulmonary insults, some differences exist. Morphological changes in lung 
parenchyma, changes in lung mechanics, and expression of MMP-9, have been 
shown to be different in pulmonary and extrapulmonary lung injury in a mouse 
model (Santos et al. 2006). Changes in lung parenchyma morphology (collagen 
deposits, fibroblast appearance) disappeared more rapidly in non-pulmonary injury. 
Additionally, in pulmonary, but not extrapulmonary injury, elastic fibres increased 
in addition to collagen fibres. A human study evaluating 21 ARDS patients has 
shown that the lung mechanics differ significantly in pulmonary and extrapulmonary 
injury (Gattinoni et al. 1998), in accordance with experimental investigations. Lung 
elastance was significantly higher in pulmonary than in extrapulmonary ARDS, 
and the chest wall elastance in turn, was higher in extrapulmonary ARDS. The 
effect of increasing PEEP level was also different, lung elastance increased and no 
recruitment was observed in pulmonary ARDS. The opposite effect was noticed 
in extrapulmonary ARDS, with a decrease in lung elastance and significant lung 
recruitment. These results clearly suggest that transpulmonary pressure is higher 
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in ARDS caused by pulmonary insult, and thus the risk of further injury caused by 
ventilatory treatment may be significant.
 Due to the inflammatory nature of ALI, a range of elements in biological 
cascades may have potential as biomarkers. Numerous markers have been studied 
in experimental studies, but considerably fewer in the clinical setting, and still fewer 
in multicentre studies. Large multicentre studies evaluating biomarkers are widely 
based on the patient population recruited to one randomised, controlled study 
evaluating the effect of low versus traditional tidal volumes on outcome in ALI/
ARDS patients (ARDSNet 2000). Table 3 presents these studies with particular 
focus on the statistical methods reported in the publications. Most of these studies 
report the association of the biomarker with the outcome measure. Most studies 
also report the results of the logistic regression analysis, performed to exclude the 
effect of the other risk factors, and to measure if the biomarker has an independent 
effect on outcome. Results concerning the clinical utility of a biomarker are, however, 
not reported. A test widely used and recommended for this purpose is the area 
under the receiver-operating-characteristic (ROC) curve (AUC) analysis. This 
method has been used widely in order to measure the discriminative value and, 
thus, the clinical utility of a biomarker (Ray et al. 2010). More advanced statistical 
solutions, namely the net reclassification improvement NRI and the integrated 
discrimination improvement IDI, have been proposed in order to further improve 
the assessment of new biomarkers (Cook et al. 2009, Pencina et al. 2008). These 
indices are based on stratification into clinical risk categories, and have already 
been reported in a biomarker study  (Wang et al. 2011). Although some weaknesses 
in reports from multicentre biomarker studies exist, the strength of these studies 
is a large patient population, and especially a controlled study design concerning 
ventilatory treatment. No systematic review of the biomarkers in ALI/ARDS have 
been performed, but recently Levitt and colleagues have published an analytical 
review (Levitt et al. 2009).
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2.2.1. pUlmONary OeDema 
Pulmonary oedema is a distinguishing feature of an acute phase of ALI (Sibbald 
et al. 1985, Ware et al. 2000). Instead of cardiac insufficiency and increased 
intravascular pressure, increased alveolar permeability is the major component in 
the pathogenesis (Staub 1978). Impaired alveolar fluid clearance has also recently 
been noticed (Ware et al. 2001b). The extent of oedema formation, as measured 
by extravascular lung water, has been shown to correlate with mortality in ARDS 
(Sakka et al. 2002). The reduction of pulmonary capillary wedge pressure, as a 
result of diuretic treatment, has also shown to correlate with improved outcome in a 
retrospective study (Humphrey et al. 1990). More recently, a randomized, controlled 
study evaluating conservative versus liberal fluid management strategy in ALI 
patients has been published (Wiedemann et al. 2006). Therein, conservative fluid 
management reduced the ventilator time and ICU length of stay without increasing 
other organ failures, such as acute kidney injury, in patients with established ALI/
ARDS after shock had reversed. This result emphasizes the importance of fluid 
overload in lung injury, and suggests the possible role of brain natriuretic peptide 
(BNP) as a biomarker.
2.2.1.1. N-terminal pro-brain natriuretic peptide (NT-pro-BNP)
BNP belongs to a family of neurohormones and has several circulatory and 
homeostatic activities. It is vasodilatory and diuretic, antagonises the renin-
angiotensin-aldosterone system, and inhibits the sympathetic nerve system. 
Myocardial cells synthesize and excrete BNP mainly in response to myocardial 
wall stretch and volume overload. Endothelin-I and angiotensin (AT)II are the most 
powerful inducers of BNP release (de Bold et al. 1996). Inflammatory pathways 
and endothelial dysfunction have also been suggested to be interacted with BNP 
(Clerico et al. 2006). BNP is a prohormone, which is proteolytically cleaved to yield 
active C-terminal and inactive N-terminal parts in a one to one ratio during its 
release from cells. NT-pro-BNP is released in equimolar amounts to active BNP, 
and thus, can be used to measure its levels. The advantage of NT-pro-BNP over BNP 
is its stability during sampling and storage (Clerico et al. 2007, Pemberton et al. 
2000). NT-pro-BNP is excreted mainly by kidneys, thus renal failure is a potential 
confounding factor in its use as a biomarker in lung failure (Forfia et al. 2005a). 
The levels of NT-pro-BNP are significantly higher than the levels of BNP but have 
shown to correlate with each other (Masson et al. 2006).
 Numerous cardiac and non-cardiac conditions cause an increase in NT-pro-
BNP levels (Zakynthinos et al. 2008). BNP has shown powerful prognostic value 
on outcome in both acute and chronic heart failure (Di Somma et al. 2010, Jarai 
et al. 2009, Latini et al. 2004) and in acute coronary syndrome (James et al. 2003, 
Jarai et al. 2005). 
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 High elevations in natriuretic peptide levels have been reported also in non-
cardiac patients. Most widely studied after cardiac patients, are patients with sepsis 
(Brueckmann et al. 2005, Charpentier et al. 2004). Some studies have reported 
a lack of ability of NT-pro-BNP to differentiate between cardiac and non-cardiac 
pulmonary oedema patients (Bajwa et al. 2008, Jefic et al. 2005), but contradictory 
results have also been published (Karmpaliotis et al. 2007). Recent studies have 
shown some prognostic value for NT-pro-BNP in hypoxic ARF patients (Karmpaliotis 
et al. 2007), and in patients with severe sepsis or septic shock (Karmpaliotis et al. 
2007, Varpula et al. 2007). In more unselected populations of critically ill patients, 
NT-proBNP has been shown to be an independent predictor of mortality (Almog 
et al. 2006, Meyer et al. 2007). The value of NT-pro-BNP, however, has remained 
unclear in the critical care setting (Christenson 2008). Recently, association between 
elevated levels of NT-pro-BNP and unfavorable outcome has been suggested in 
mechanically ventilated (Kotanidou et al. 2009) and ARDS (Bajwa et al. 2008) 
patients. Studies evaluating BNP or NT-pro-BNP in mechanically ventilated, ARF, 
or ARDS patients are presented in Table 4.
table 4. Studies evaluating brain natriuretic peptides (BNp or Nt-pro-BNp) in mechanically 
ventilated,  arF, or arDS patients.
patients 
population
Number of 
patients 
/ non-survivors
Study aim result
jefic 2005 Hypoxic 
respiratory failure
41/17 (41%)
(30-day)
1) can NT-pro-BNP 
differentiate between 
patients with high vs. low 
PAOP pulmonary oedema 
2) does NT-pro-BNP
predict 30-day mortality
1) NT-pro-BNP does 
not correlate with 
PAOP
2) no value in 
mortality prediction
karmpaliotis 
2007
Hypoxic 
respiratory failure 
(PaO2/FiO2 <300 
mmHg)
80/ NA 1) does BNP assist in 
diagnostics of cardiogenic 
vs. non- cardiogenic 
pulmonary oedema?
2) utility of BNP in 
prognostic evaluation
1) BNP is useful in 
excluding cardiogenic 
pulmonary oedema
2) associates with 
hospital mortality in 
all patients
Berdal 2008 MV > 48 hours 70/25 (36%) 
(30-day)
Prognostic value of 
NT-pro-BNP on 30-day 
mortality
Independent 
predictor of mortality, 
AUC 0.74 
Bajwa 2008 ARDS 177/70 (40%) 
(60-day)
1) to evaluate NT-pro-BNP 
levels in ARDS patients
2) to examine the diag-
nostic and prognostic 
value 
1) elevated levels 
found in ARDS, 
median 3180 pg/ml 
2) no diagnostic 
value, independent 
predictor of 
60-mortality
kotanidou 
2009
Unselected, 
non-cardiac ICU 
patients, all with 
MV
233/98 (42%) 
(ICU)
to evaluate prognostic 
value of NT-pro-BNP 
independent 
predictor of ICU 
mortality
ARDS, acute respiratory distress syndrome; ARF, acute respiratory failure; ICU, intensive care unit; 
MV, mechanical ventilation; NA, not available; NT-pro-BNP, aminoterminal pro-brain natriuretic 
peptide; PAOP, pulmonary artery occlusion pressure 
26
Review of the literature
2.2.2. mechaNIcal INjUry 
Ventilatory support is a life saving treatment in ARF, but it can also augment the 
existing lung injury and even cause injury to previously healthy lungs. This injury, 
referred as ‘ventilator associated lung injury’ (VALI), may originate simply due to 
mechanistic reasons, since lungs exhibit a non-homogeneous structure with aeration 
differing widely under mechanical ventilation. This can cause powerful traction 
forces to occur in the intermediate region between areas of different aeration, as 
shown by Mead and colleagues in their classical study (Mead et al. 1970). Early 
animal studies have shown that ventilation with high tidal volumes and high 
inspiratory pressures is injurious to lungs (Dreyfuss et al. 1985, Kolobow et al. 
1987, Tsuno et al. 1991, Webb et al. 1974). In humans, studies have mostly focused 
on patients with the diagnosis of ALI or ARDS. The first observations of reduced 
mortality, when tidal volumes and inspiratory pressures had been limited in ARDS 
patients, were published by Hickling and colleagues (Hickling et al. 1990, Hickling 
et al. 1994). These studies were retrospective and observational and had no control 
groups, but raised much interest in the issue. 
The issue of injurious ventilation was further studied by including 44 patients 
in a RCT evaluating the impact of ventilatory settings on inflammatory mediators 
(Ranieri et al. 1999). Results confirmed that ventilation with high tidal volume (11 ml/
kg) and inspiratory pressure (31 cmH2O) caused an increase in both bronchoalveolar 
lavage (BAL) fluid and plasma levels of TNF-α, interleukin(IL)-6, and TNF receptors. 
Lung protective ventilation, on the contrary, resulted in a decrease of these mediators. 
These results support the hypothesis that ventilator treatment may induce and 
augment the systemic inflammatory response and cause remote organ failure that 
may ultimately lead to multiple organ failure. Concurrently, four randomised, 
controlled studies evaluating the effect of tidal volume limitation on outcome in 
ARDS patients were published (Amato et al. 1998, Brochard et al. 1998, Brower 
et al. 1999, Stewart et al. 1998). One study showed a large decrease in the 28-day 
mortality in the low tidal volume group (38%) when compared to traditional tidal 
volume group (71%) (Amato et al. 1998), but high mortality in the control group has 
raised criticism. Three other studies, with enrolled patient numbers varying from 
52 to 120, however, failed to show any outcome benefit associated with low tidal 
volume strategy (Brochard et al. 1998, Brower et al. 1999, Stewart et al. 1998). More 
recently, a large randomized, controlled study comparing low (6 ml/kg predicted 
body weight, PBW) and traditional (12 ml/kg PBW) tidal volumes in ARDS was 
performed, with the results showing a significant decrease in hospital mortality in 
the low tidal volume group (31%) versus the traditional tidal volume group (40%) 
(ARDSNet 2000). These somewhat contradictory results were discussed in a meta-
analysis (Eichacker et al. 2002). Criticism has been presented especially concerning 
the two beneficial studies and their control groups, in which the ventilatory strategy 
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was not based on the best practise at the time. Tidal volumes, as well as inspiratory 
pressures, were higher than used routinely and showed significant increase after 
the randomisation of the study. Thus, the meta-analysis presented that the positive 
results of two beneficial studies may have rather been a result of the injurious 
ventilatory strategy in the control groups rather than better treatment in the low 
tidal volume groups (Eichacker et al. 2002). The effect of large tidal volumes have, 
however, been shown to be clearly deleterious (Amato et al. 1998, ARDSNet 2000). 
Recommendations to use low tidal volumes in septic ALI/ARDS patients have been 
presented (Dellinger et al. 2008), mainly based on the largest multicentre study. 
The precise size of the tidal volume causing the least injury still remains open.
When ARDSNet researchers tested several lung-injury biomarkers (vide supra), 
plasma RAGE, a marker of epithelial injury, was shown to decrease significantly 
more in the low tidal volume group. This suggests that the better outcomes achieved 
with a lower tidal volume strategy, may be due to a lesser amount of epithelial injury 
(Calfee et al. 2008). The same kind of effect was seen in IL-6 levels, which decrease 
significantly in both groups from baseline to day 3, but lowered even more in the 
lower tidal volume group (Parsons et al. 2005a).  
Given these observations in ALI and ARDS patients, the field of interest has 
extended to mechanically ventilated patients who present risk factors for ALI at 
baseline, but no pre-existing condition. In a retrospective analysis of 332 mechanically 
ventilated patients without ALI at baseline, tidal volume per PBW was found to 
be an independent predictor for the development of ALI (Gajic et al. 2004). Later, 
an observational cohort study comparing two subsequent groups of mechanically 
ventilated patients without ALI at baseline, showed a significant reduction in tidal 
volumes as well as in the incidence of ALI  (Yilmaz et al. 2007). An intervention in 
this study, carried out between the patient cohorts, was an introduction of protocol 
to limit tidal volumes and restrict transfusion policy. The magnitude of the decrease 
in ALI incidence over time (from 28% in 2001 to 10% in 2005) as well as in tidal 
volumes (from 10.6 to 7.7. ml/kg PBW) is impressive, especially regarding the 
simplicity of the intervention. The study setting with historical controls, however, 
may confuse the results. In a more recent report, the results of earlier studies were 
confirmed in a prospective, randomized setting evaluating the effect of tidal volume 
on ALI development in 150 patients (Determann et al. 2010). ALI incidence was 
13.5% in a conventional tidal volume group (10 ml/kg PBW) versus 2.6 % in a low 
tidal volume group (6 ml/kg PBW), and the study was stopped prematurely for safety 
reasons. In both groups, plasma IL-6 levels decreased over time, but the decrease 
was more pronounced in the low tidal volume group. This result suggests that 
ventilation with lower tidal volumes results in a lower level of systemic inflammation. 
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2.2.3. epIthelIal INjUry 
Surfactant proteins A (SP-A) and D (SP-D) are glycoproteins that belong to a family 
of collectins. They are secreted by alveolar epithelial type II cells. SP-A is the most 
abundant protein in surfactant, acting in the regulation of surfactant homeostasis 
and in host defence (Levine AM 1998, Wright JR 1993). It has been shown to inhibit 
the apoptosis of alveolar epithelial type II cells in vitro (White et al. 2001), and 
SP-A concentrations have been reported to decrease in a BAL fluid of early ARDS 
patients (Greene et al. 1999). SP-D, on the other hand, has an effect on surfactant 
phospholipid homeostasis (Botas et al. 1998), and plays an important role in the 
regulation of lung inflammation (Greene et al. 1999) and innate immunity in the 
lung (Wright 1997). Both surfactant proteins have been evaluated in 38 invasively 
ventilated patients, and results suggested that low oedema fluid levels of SP-A and 
high plasma levels of SP-D may be associated with worse outcome (Cheng et al. 
2003). Later, these proteins were studied in patients from a large multicentre study, 
which was originally designed to compare two ventilatory strategies (ARDSNet 
2000). SP-A did not show association with any clinical outcome measure (Eisner et 
al. 2003). High plasma SP-D levels, on the contrary, were associated with increased 
mortality and morbidity, and showed attenuation with low tidal volume strategy.
 Clara cell secretory protein 16 (CC16) is a major protein secreted by Clara cells, 
multifunctional epithelial cells that act in the repair process of damaged alveolar 
epithelium (Broeckaert et al. 2000). CC16 levels have been shown to increase after 
five hours of mechanical ventilation for elective surgery but tidal volume did not 
affect its levels (Determann et al. 2008). In a small multicentre study, serum CC16 
levels were associated with an increased risk of death at 28 days, however the AUC 
for the prediction of death was low at 0.68 (Lesur et al. 2006).
 Receptor for advanced glycation end-products (RAGE) is a multi-ligand receptor 
expressed mainly by lung epithelial type I cells (Uchida et al. 2006). Cells from 
other organs, including nervous system and vascular endothelium, can also produce 
RAGE, but it is most abundant in lung (Brett et al. 1993). In immunoelectron 
microscopy, RAGE has shown to be situated in the basal membrane of type I 
epithelial cells in rat lungs (Shirasawa et al. 2004). Its ligands include, among 
others, cytokine-like mediators like S100/calgranulins, and high-mobility group 
box-1, a nuclear protein related to cell necrosis. Ligand binding to RAGE leads 
to the activation of proinflammatory pathways (mediated by nuclear factor-κB), 
suggesting that it plays a potential role in systemic inflammation (Chavakis et 
al. 2004). Indeed, RAGE knockout mice have been shown to be able to resist 
experimental septic shock (Liliensiek et al. 2004). In addition, an association with 
chronic inflammatory stages, including diabetic complications and amyloidosis, 
has been detected (Schmidt et al. 2001). RAGE has been reported to consist of 
three domains, including a soluble form of RAGE (sRAGE) that represents the 
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extracellular domain (Uchida et al. 2006). It is thought to emerge into alveolar 
oedema fluid and plasma by metalloproteinase cleavage (Zhang et al. 2008) or 
it may represent endogenously secreted RAGE variants (Cheng et al. 2005). In 
patients with ALI, high levels of sRAGE has been detected in pulmonary oedema 
fluid and plasma (Uchida et al. 2006). In contrast, in mechanically ventilated 
hydrostatic pulmonary oedema patients, RAGE was detected in oedema fluid, 
although at lower levels than in ALI patients, but not in plasma. This finding 
strengthened the hypothesis that lungs would be a predominant source of sRAGE 
and suggested that mechanical ventilation may cause slightly increased sRAGE 
levels in hydrostatic pulmonary oedema patients. In a multicentre study that 
evaluated sRAGE in 676 ALI/ARDS patients, increased levels associated strongly 
with a clinical severity of lung injury (Calfee et al. 2008). In the same study, baseline 
plasma sRAGE was an independent predictor of 180 day mortality, but only in the 
group of 12 ml/kg tidal volume. These results have provided clinical evidence for 
epithelial injury in the pathophysiology of ALI, as well as the possible mechanism 
by which the use of low tidal volumes may affect the outcome. In a more recent 
study, levels of sRAGE were significantly higher in ALI/ARDS patients with or 
without severe sepsis or septic shock when compared to septic patients without 
ALI/ARDS, which reinforces even further the likely role of lungs as a primary 
source of sRAGE (Jabaudon et al. 2011)
2.2.4. eNDOthelIal INjUry
Von Willebrand factor (vWf) is a large multimeric protein that is secreted by 
endothelial cells and to a smaller extent by platelets. It acts in primary hemostasis 
by bridging platelets to endothelium, and as a carrier protein for factor VIII. Elevated 
levels have been found in patients with ARF caused by different reasons (Carvalho 
et al. 1982). VWf levels 450% or greater have been shown to be associated to the 
development of ALI in patients with non-pulmonary sepsis (Rubin et al. 1990). 
Nonetheless, contradictory results regarding the prognostic property of increased 
vWf levels have been published (Moss et al. 1995). Differences in the definitions 
of ALI and ARDS, as well as in patient material may explain this. More recently, 
increased levels of vWf  have shown to be a potential prognostic biomarker of 
endothelial injury (Ware et al. 2001a), which was later confirmed in a large 
multicentre study (Ware et al. 2004). The ventilatory strategy, thus low tidal volume 
(6 ml/kg) as compared to conventional tidal volume (12 ml/kg), did not affect vWf 
levels, suggesting that the effect of the lung protective ventilatory strategy is primarily 
based on the attenuation of the epithelial injury. The exact source of vWf in ALI 
remains unclear. Pulmonary endothelium seems the most obvious place of increased 
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release, but systemic endothelium has also been proposed. This hypothesis offers 
one potential explanation for a pathway of indirect pulmonary injury. In healthy 
volunteers, infusion of tumor necrosis factor-α increased the vWf concentrations 
and simultaneously reduced the endothelial staining in skin biopsy, suggesting 
release of vWf from systemic endothelium (McGill et al. 1998). 
 Intercellular adhesion molecule-1 (ICAM-1) is present in endothelial cells and 
leukocytes and is considered to be a marker of both endothelial and epithelial injury 
(Conner et al. 1999). The production of ICAM-1 is induced by several cytokines, 
including IL-1 and TNF-α, and can be suppressed by glucocorticoids (van de Stolpe et 
al. 1996). During inflammation and injury, it mediates leukocyte migration through 
endothelium (Hordijk 2006). The exact role of ICAM-1 in the epithelium is not clear, 
but it has been shown to accelerate the inflammatory reaction in injury by activating 
alveolar macrophages (Schmal et al. 1998). In contrast, inhibition of lymphocyte 
adhesion by soluble ICAM-1 has also been noticed, suggesting the possibility of 
anti-inflammatory activity in some circumstances (Shingu et al. 1994). In a single 
centre study, plasma ICAM-1 levels were found to be higher in ALI patients than in 
the control group of hydrostatic pulmonary oedema patients (Calfee et al. 2009). 
Although a large multicentre study has shown the plasma levels to be predictors of 
some outcome parameters (ventilator-free days, organ-failure free days), its value as 
a mortality predictor seems more uncertain (Calfee et al. 2009). In an earlier study, 
ICAM-1 was unable to predict either the development of ARDS or the mortality, but 
the patient number of this study was small for predictive purposes (Agouridakis et 
al. 2002). 
2.2.5. SyStemIc INFlammatION
Cytokines are an essential part of host defense mechanisms, acting in both innate 
and adaptive immunity. In critically ill patients, TNF-α and interleukin (IL)-1 are 
the main proinflammatory cytokines, while IL-6 has anti- and proinflammatory 
actions, and IL-10 is solely anti-inflammatory (Oberholzer et al. 2000). Cytokines 
are secreted by mononuclear cells, mainly monocytes and macrophages, in response 
to microbial antigens and inflammation. Proinflammatory cytokines activate further 
macrophages and neutrophils, induce endothelial cell production of adhesion 
proteins (including ICAM-1), mediate neutrophil migration, and stimulate the 
synthesis of acute phase proteins (Riedemann et al. 2003). IL-10 downregulates 
many aspects in acute inflammatory process, including proinflammatory cytokine 
production of activated neutrophils and macrophages (Opal et al. 2000).
 Increased levels of cytokines have been detected in patients with ARDS and 
persistently increased levels in plasma (Meduri et al. 1995) and BAL (Goodman 
et al. 1996) have been shown to associate with poor outcome. In a multicentre 
31
trial, levels of IL-6, IL-8 (another proinflammatory interleukin), and IL-10 were 
all significantly higher in non-survivors than survivors at baseline and at day 3 
(Parsons et al. 2005a). The lung protective ventilation strategy was associated 
with a greater decrease in IL-6 and IL-8 concentrations, suggesting that injurious 
ventilation sustains the inflammatory reaction in lungs. More recently, in a small 
prospective study where several biomarkers were tested in 50 ALI patients, levels 
of IL-8, but not IL-6, differed between survivors and non-survivors (McClintock et 
al. 2008). These somewhat conflicting results are most probably due to inadequate 
sample size in the latter study.
 TNF-α is known to be an important mediator of ALI (Parsons et al. 1992, Tracey 
et al. 1988). In an animal study, a recombinant human soluble TNF receptor (TNFR) 
fusion protein, which is able to bind to TNF-α, thus inhibit its activity, attenuated 
the development of ALI (Wolthuis et al. 2009). Clinical studies have not, however, 
been able to confirm the association with TNF-α levels and clinical outcome in ALI 
patients or patients with risk factors for ALI (Park et al. 2001, Pittet et al. 1997). It 
has been suggested that this may be due to soluble TNF receptors I and II (sTNFRI 
and II). TNFRI and II are released widely from variety of cells, but epithelial cells 
mainly express TNFRI. Inflammatory stimuli are reported to cause shedding of 
these receptors from cell surfaces (Mackay et al. 1993)F. sTNFRs are able to bind 
TNF and thus, by competing with the cell surface receptors, downregulate TNF 
activity. Elevated levels of sTNFRs have been reported after trauma (Hensler 2002) 
and coronary bypass operation (ElBarbary MKKS 2002). Based on these findings, 
Parsons and colleagues evaluated the levels of TNFRI and II in ALI patients first 
in a single centre study and later in a multicentre trial (Parsons et al. 2005b). In 
a single centre study, levels of sTNFRI and II in patients with risk factors for ALI 
were not able to predict the development of ALI. In a multicentre trial of 562 ALI/
ARDS patients randomized to 6 ml/kg versus 12 ml/kg ventilatory strategy, sTNFRI 
and II were independent predictors of mortality. sTNFRI, but not sTNFRII, was 
attenuated by the 6 ml/kg ventilation strategy. Additionally, sTNFRI was reported 
to be released from alveolar epithelial cells in an experimental substudy, findings 
supporting the epithelial origin of sTNFRI. It is of interest to note that TNF-α levels, 
measured from a subgroup of 377 patients, were detectable in only 34 (9%) patients 
and were comparable in survivors and non-survivors. These results suggest that 
sTNFRs are markers of inflammation, and perhaps also of epithelial injury in ALI. 
Additionally, TNF-α does not appear to be an appropriate biomarker. 
2.2.6. cOagUlatION
Inflammation and coagulation cascades co-operate closely (Levi et al. 1999). The 
early mediators of the inflammatory process, TNF-α, IL-1 and IL-6, are known to 
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activate coagulation via the tissue factor (TF) pathway (or extrinsic pathway), and 
also to stimulate the release of plasminogen activator inhibitors (PAI), resulting 
in decreased fibrinolysis. The activation of coagulation proceeds primarily via an 
extrinsic pathway where TF binds to factor VII (fVII) in sepsis (Biemond et al. 1995), 
and in ARDS and ventilator associated pneumonia (Idell et al. 1987a, Schultz et 
al. 2004). The activated TF/fVIIa complex further activates fX to fXa leading to 
alveolar thrombin, and eventually to fibrin formation. 
 In addition to its hemostatic effect, thrombin has a key role in pulmonary 
fibroproliferation, which is mediated by protease activated receptor -1 (PAR-1), 
a major thrombin receptor (Howell et al. 2002). The expression of PAR-1 on cell 
surfaces can be upregulated by proinflammatory and profibrotic mediators (Sokolova 
et al. 2007), and it is proposed to play a central role in coordinating the interactions 
between coagulation, inflammation, and fibrosis in lung injury (Chambers 2008). 
In addition to thrombin, fXa is also able to activate PAR-1 and induce fibrotic 
responses in the mouse lung (Blanc-Brude et al. 2005, Scotton et al. 2009). In 
an animal study, PAR-1-deficient mice were protected against pulmonary fibrosis 
(Howell et al. 2005). The protective action of PAR-1 deficiency was accompanied 
by the reduction of proinflammatory and profibrotic mediators, TGF-β1 among 
others, known to be induced by PAR-1. In addition, direct inhibition of thrombin 
has been shown to reduce lung collagen accumulation in an experimental study 
(Howell et al. 2001). Indeed, reports of the actions of PAR-1 have been limited to 
experimental settings. 
 The natural inhibitor of coagulation, namely activated protein C (APC) has an 
essential role in the regulation of coagulation. Its role in human sepsis has been 
studied extensively, and a growing body of evidence suggests that it is  also involved 
in ALI. APC has antithrombotic, profibrinolytic, and anti-inflammatory properties. 
Its concentrations in plasma and BAL fluid were reported to be significantly 
lower than normal in 45 patients with ALI or ARDS, and lower levels have been 
associated with increased hospital mortality, independent of sepsis (Ware et al. 
2003). Later, the results were confirmed in a multicentre study of 779 patients that 
showed protein C to be an independent predictor of hospital mortality (Ware et al. 
2007). Additionally, plasminogen activator inhibitor-1 (PAI-1) concentrations were 
evaluated as markers of fibrinolysis, which was noticed to decrease. PAI-1 also was 
an independent predictor of death, but more importantly, a synergistic interaction 
between protein C and PAI-1 was observed, where low protein C and high PAI-1 levels 
coincided. The data suggests that when either fibrinolysis or coagulation impairment 
exists, the other is able to compensate partly, the situation being contrary if both are 
impaired. More recently, in another study with 50 patients, levels of other markers 
of inflammation, coagulation, and fibrinolysis were also evaluated in addition to 
protein C. All markers (IL-8, sICAM-1, protein C, thrombomodulin, and PAI-1) 
except IL-6, differed significantly between survivors and non-survivors, confirming 
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the broad abnormalities in these pathways in ALI (McClintock et al. 2008). 
 A decade ago, a multicentre RCT evaluating recombinant human APC versus 
placebo in severe sepsis, showed a significant reduction in overall mortality (Bernard 
et al. 2001). Additionally, those patients with respiratory dysfunction and treated 
with APC, recovered faster. Thus far, APC has remained the only specific treatment 
in severe sepsis. However, the manufacturer has just withdrawn the medicine from 
the worldwide market after the preliminary results of a large multicentre study which 
did not show any difference in the mortality between APC and placebo in septic 
shock patients (Eli Lilly, press release, October 2011). Based on earlier findings and 
the pathophysiological rationale, a multicentre phase II study evaluating APC and 
placebo in non-septic ALI patients was performed; however, the study was stopped 
early because of no effect in the treatment group (Liu et al. 2008). 
 PAI-1 inhibits plasminogen activator, the action leading to decreased fibrinolysis. 
PAI-1 release is increased by proinflammatory mediators, TNF-α and IL-1. Elevated 
levels of PAI-1 in plasma and especially in BAL fluid has been reported in patients 
with ALI in comparison to hydrostatic pulmonary oedema, suggesting inhibition 
of fibrinolytic activity in ALI  (Prabhakaran et al. 2003). The levels of plasma PAI-
1 were significantly higher in non-survivors than survivors, a result that was later 
confirmed in a multicentre study, which showed PAI-1 to independently predict 
mortality (Ware et al. 2007), as mentioned earlier.
 
Nitric oxide (NO) is a marker of oxidative injury (Baylis et al. 1998). It reacts with 
superoxide ion and forms peroxynitrite, a highly reactive intermediate. It nitrates 
and oxidizes and, thus, inactivates proteins such as SP-A, and inhibits their functions 
(Ehrhart et al. 2000). Due to the short half life of peroxynitrite, nitric oxide species 
(NO, nitrate and nitrite) are used to measure its activity. Studies on animal lung 
injury have suggested that in lung injury, BAL fluid levels of nitric oxide species 
are higher than in controls (Enkhbaatar et al. 2003, Frank et al. 2003). A single 
center clinical study confirmed these results in humans, and also suggested that 
the higher NO levels in BAL fluid associate with mortality (Sittipunt et al. 2001). 
In a multicentre study, however, the results were contrary, where higher levels of 
urine NO were associated with better outcome by means of reduced mortality and 
fewer days in a ventilator and with organ failure (McClintock et al. 2007). The role 
of NO as a biomarker of ALI, thus, remains uncertain, and requires further studies.
 Desmosine, a breakdown product of elastin, has been studied in different chronic 
pulmonary diseases, including COPD, cystic fibrosis, and tobacco use (Bode et al. 
2000, Cocci et al. 2002). Desmosine is excreted to urine, and is a selective marker 
of elastin breakdown. Urine desmosine has shown promise as a marker of mortality 
in a multicentre study, but ventilatory strategy did not associate with desmosine 
levels (McClintock et al. 2006). The prognostic role of urine desmosine in ALI 
remains unconfirmed. 
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2.2.7. apOptOSIS
Apoptosis plays an important role in the maintenance of normal tissue structure. 
Apoptosis, a controlled cell death, can be activated in several ways, as genetic 
“programmed cell death”, via an external pathway, and through receptor-ligand 
interactions (Perl et al. 2005a). As a result of cell death, DNA is fragmented and 
can be found in the circulation. Concerning the pathogenesis of ALI, apoptosis may 
play role at several stages. 
 The apoptotic death of alveolar epithelial cells has been suggested to play a 
major role in the development of ALI (Matute-Bello et al. 2001a, Matute-Bello et 
al. 2001b). The mechanisms of epithelial cell apoptosis are not well understood, 
but the role of an “extrinsic” or death receptor pathway is supported by several 
studies (Matute-Bello et al. 1999, Perl et al. 2005b). This pathway is mediated by 
the cell surface receptor Fas (also known as CD95) and its natural ligand, Fas-ligand, 
and can be initiated in response to different soluble mediators. The expression of 
Fas-receptor on the surfaces of alveolar cells is increased by the stimulation of 
inflammatory mediators (Kitamura et al. 2001). Fas-ligand can exist in soluble and 
membrane bound form, and both are able to activate Fas-receptor and start the 
apoptotic pathway. In an animal study, rabbits ventilated with high tidal volume, 
presented increased apoptosis, measured by plasma levels of Fas-ligand (Imai et al. 
2003). Caspases, a family of proteolytic enzymes, are thought to have an essential 
role in intracellular pathways resulting in DNA cleavage as a final step (Perl et al. 
2005a). Fas-ligand has shown to be present in a biologically active form in BAL 
fluid from early ARDS patients, and high concentrations associated with worse 
outcome (Matute-Bello et al. 1999). Angiotensin (AT) II has been shown to induce 
epithelial cell apoptosis in vitro via Fas/Fas ligand –pathway (Wang et al. 1999), 
and increased amounts of ATII have been detected in BAL fluid in ARDS (Idell et 
al. 1987b).
 Neutrophilic apoptosis is another important mechanism by which apoptosis 
has been shown to be involved with ALI (Figure 1). Neutrophils are important 
cells in the first line of host defence against pathogens. They migrate through 
the injured endothelium to the alveolar space, where they secrete proteases, 
leukotriens, oxidants, and platelet activating factor (PAF), thus, further enhance 
the inflammatory reaction. After this, neutrophils apoptose and are cleared from 
the injury site by phagocytotic cells like macrophages. In a rat lung injury model, 
neutrophil apoptosis has been reported to be inhibited in the early moments 
after experimental lung injury, however  recovery was evident at 24 hours with 
a clear clinical and histological picture of early resolution of injury (Hussain et 
al. 1998). Another rat study has shown an enhancement of neutrophil apoptosis 
to associate with decreased mortality and lung injury (Sookhai et al. 2002). Also 
in animal studies, the stimulation of neutrophil release from bone marrow with 
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human granulocyte colony-stimulating factor (G-CSF) (filgrastim) has been shown 
to worsen lung function in ALI (King et al. 1995) and the outcome in pneumonia 
(Held et al. 1998). On the contrary, in human studies these detrimental effects of 
G-CSF have not been observed in patients with community acquired pneumonia 
(Nelson et al. 1998) or in mechanically ventilated ICU patients (Pettila et al. 2000). 
Clearance failure of apoptotic neutrophils is associated with increased inflammation 
and decreased survival in the CD44 deficient mouse model of acute lung injury 
(Teder et al. 2002). The phagocytic activity of apoptotic neutrophils attenuates the 
production of proinflammatory cytokines and stimulates the production of anti-
inflammatory mediators, thus, favouring resolution of inflammation. In contrast, 
phagocytotic clearance of necrotic cells is related to the release of proinflammatory 
cytokines and thus, potentially inducing tissue injury (Fadok et al. 1998).
2.2.7.1 Plasma cell-free DNA
The detection of fetal cell-free DNA in maternal blood has been used in the evaluation 
of prenatal conditions (Wright et al. 2009). It has also been studied widely in 
different malignancies, but its role in that area remains uncertain (van der Vaart 
et al. 2010). Studies have also evaluated cell-free DNA in different states of acute 
illness, including abdominal pain, chest pain, stroke, pancreatitis, trauma, ischemic 
cardiomyopathy, and resuscitated patients (Arnalich et al. 2010b, Gornik et al. 
2009, Lo et al. 2000, Rainer et al. 2008, Rainer et al. 2006, Rainer et al. 2003, 
Zaravinos et al. 2011). Few studies reporting critically ill patients have been published 
(Martins et al. 2000, Rhodes et al. 2006, Saukkonen et al. 2008, Saukkonen et al. 
2007, Wijeratne et al. 2004). Table 5 summarizes studies, which have evaluated 
the prognostic value in ICU patients. 
 The levels of cell-free DNA in plasma can reflect different phenomenon. In ALI, 
the apoptosis of neutrophils and lung epithelial cells most likely plays an important 
role, as reviewed above. Cell necrosis and apoptosis are well known origins of cell-
free DNA in blood (Jung et al. 2010). In healthy individuals apoptosis is considered 
a primary mechanism for DNA occurrence in blood (Suzuki et al. 2008). Active 
release of DNA fragments from living cells has also been described. DNA can be 
extracted from both serum and plasma, however plasma samples are more reliable 
because serum samples can contain DNA originating from in vitro lysis of leukocytes 
(Lee et al. 2001).
 There is a lack of knowledge regarding the elimination process of cell-free DNA 
from blood. It is known that a half-life of four to 30 minutes is evident for the 
clearance of fetal DNA from maternal blood after delivery (Lo et al. 1999). Renal 
failure does not seem to affect the elimination since no differences were detected 
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in the concentrations of plasma cell-free DNA between healthy volunteers and 
patients with chronic renal failure (Garcia Moreira et al. 2006). Decreased activity 
of deoxyribonuclease as a reason for high cell-free DNA concentration has been 
reported (Cherepanova et al. 2008), but the activity of plasma nucleases in the 
elimination process is considered insignificant (Jung et al. 2010).
table 5. Studies evaluating prognostic value of plasma cell-free DNa in critically-ill patients
Number patients included
best cut-off
(ge/ml)
aUc 
(mortality)
Sensitivity, specificity 
for hospital mortality
wijeratne 2004 96
Consecutive 
patients 
admitted in ITU
6100 0.889 (ITU) sensitivity 85%specificity 80%
rhodes 2006 52 Unselected ICU admissions 19 000
0.84 (ICU) *
0.79 (hospital)
sensitivity 81% *
specificity 81% *
Saukkonen 2007 228 Unselected ICU admissions NA NA NA
Saukkonen 2008 255 Severe sepsis or septic shock 12 000
0.71 (ICU) *
0.61 (hospital)
sensitivity 67% *
specificity 67% *
AUC, area under receiver operating curve; GE, genome equivalent; ICU, intensive care unit; ITU, 
intensive treatment unit; NA, not available 
* sensitivity and specificity for ICU mortality
2.2.8. FIBrOgeNeSIS 
The development of lung injury has been previously considered to take place in 
subsequent steps where the accumulation of collagen starts only after five to seven 
days. A growing collection of data, however, supports the likelihood that the process 
of fibrogenesis starts early after the insult (Chesnutt et al. 1997, Entzian et al. 1990, 
Liebler et al. 1998). Indeed, it has been shown that the collagen messenger RNA 
expression is upregulated immediately after cardiopulmonary bypass, an insult 
known to predispose to ARDS (Deheinzelin et al. 1997). 
 The cells responsible for collagen production are myofibroblasts that arise from 
the activation of tissue fibroblasts, bone-marrow-derived fibroblasts, and fibroblasts 
experiencing epithelial-to-mesenchymal transition (Kisseleva et al. 2008). Fibrin 
is thought to act as a provisional matrix, on which the proliferation and collagen 
production of myofibroblasts takes place (Pohl et al. 1979). A proinflammatory 
mediator, TGF-β1, has a major role in the activation of fibroblasts in wound healing 
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as well as in idiopathic pulmonary fibrosis (Scotton et al. 2007, Singer et al. 1999). 
A latent form of TGF- β1 is known to be activated by numerous stimuli, including 
metalloproteinases, plasmin, and reactive oxygen species, all acting in the process 
of acute inflammation (Mu et al. 2002). The role of TGF-β1 in ARDS has been 
reported for the first time in the study of 13 early ARDS patients, whom showed 
elevated TGF- β1 activity in BAL fluid (Fahy et al. 2003). 
2.2.8.1. Markers of collagen metabolism 
Collagen types I and III are the dominating proteins of extracellular matrix and 
are produced in response to tissue injury. The balance of collagen synthesis and 
degradation is important in order to maintain tissue integrity. In fibrosis, excessive 
collagen accumulation in tissues leads to organ failure (Adler et al. 1989, Eddy 
1995, Weber 1989). 
 Collagen III, a reticular fibre, is synthesised quickly by young fibroblasts and 
is common in granulation tissue. The synthesis of collagen I, the most abundant 
collagen in human body, takes place later in the course of fibrogenesis and its 
structure is more stable and resistant, confirming the breaking strength of tissue. 
Endoplasmic reticulum of myofibroblasts synthesises α-chains, which subsequently 
combine, in a zipper-like manner, to form a triple helix structure of procollagen 
molecule. After secretion to the extracellular space, pro-collagen molecules first go 
through proteolytical cleavage of carboxy(C)- and amino(N)-terminal ends, and 
then connect with each other to form insoluble collagen fibrils. These fibrils arrange 
further to form collagen fibres (Myllyharju et al. 2004). C- and N-terminal ends of 
procollagen, by-products of collagen synthesis, are produced in equimolar amounts 
to collagen and, thus, reflect the rate of collagen synthesis. Human studies have 
shown increased serum levels of procollagen III in trauma patients (Waydhas et 
al. 1993). In ALI and ARDS patients, procollagen accumulation in BAL fluid has 
been reported, indicating increased collagen synthesis in lungs (Armstrong et al. 
1999, Chesnutt et al. 1997, Clark et al. 1995).
 Studies on ICTP, the degradation product of collagen type I, cover mainly diseases 
of skeleton, a main source of collagen breakdown products (Heider et al. 2006). 
In critically ill patients, elevations of ICTP, has been measured in two studies in 
patients with severe sepsis (Gaddnas et al. 2009, Wenisch et al. 1996). 
 Concentrations of all collagen metabolites measured from serum reflect the 
metabolism of the whole body. Studies have shown that in lungs (Marshall et al. 
2000) increased collagen synthesis is obvious, but for example in undamaged skin 
of septic patients, the synthesis is depressed (Gaddnas et al. 2010).
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2.2.9. reSOlUtION
Apoptosis of myofibroblasts responsible for producing collagens, is a key step in 
cessation of the repair process (Weber 1997). Following apoptosis of myofibroblasts, 
and the subsequent reduction in TGF-β1 secretion, the process of repair abates 
(Hussain et al. 1998).
 The recovery of alveolar fluid clearance has been suggested to have a major role 
in the resolution of ALI (Ware et al. 2001b). Traditionally, alveolar epithelial type II 
cells have been considered to be responsible for the active Na+ and Cl- -ion transport, 
which is followed by inactive water shift through type I epithelial cells. Recently, 
epithelial type I cells have been shown to play a major role in ion transport and 
its following fluid shift (Johnson et al. 2006). The role of special water channels, 
“aquaporins”, in the alveolar fluid clearance has been challenged (Verkman 2007). 
β-adrenergic agonists are known to stimulate sodium transport and, thus, increase 
alveolar fluid clearance, an observation from isolated human lung (Sakuma et al. 
1994) and from an animal study (McAuley et al. 2004). More recently, the effect of 
intravenous infusion of salbutamol has been studied in a single centre RCT including 
40 patients with ALI/ARDS. Patients in the salbutamol group had significantly 
lower lung water and plateau pressure at day seven when compared to the placebo 
group (Perkins et al. 2006). In contrast, amiloride and propranolol decrease sodium 
transport.
 Type II alveolar epithelial cells (AEC) are responsible for the production of 
surfactant, and act in the first line of host defence, but are essential also in the 
repair process. Type II AECs are mesenchymal cells with a pluripotent character, 
and they are able to differentiate to type I epithelial cells and restore the damaged 
epithelium (Mason 2006). The apoptosis is thought to play a role, in addition to 
myofibroblasts, in the clearance of neutrophils and the excess type II AECs. 
 In conclusion, many biomarkers have shown distinct abnormalities in patients 
with ALI, but none studied so far can be considered useful in clinical practise. The 
knowledge of the pathophysiological pathways, however, has increased enormously, 
and will hopefully yield new treatments for ALI in the future.
2.3. meaSUrINg OUtcOme
Outcome can be measured with multiple parameters. Short-term outcome is 
mandatory for long-term outcome, but long-term outcome is critically important. 
ICU and hospital mortalities are commonly used as short-term outcome parameters, 
but recently longer periods of survival have been used increasingly as outcome 
measures (Bellomo et al. 2009, Finfer et al. 2009). Even five year survival rates 
after ARF have been reported (Garland et al. 2004). The need for mechanical 
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ventilation has been predicted to increase with the ageing population (Needham et al. 
2005). Along with the increased costs of intensive care, associated with mechanical 
ventilation, the importance of studies of long-term outcome is highlighted. Reporting 
health related quality of life after critical illness has gained increasing interest. 
Few studies reporting quality adjusted life years, or cost-effectiveness, have been 
published (Angus et al. 2001, Linko et al. 2010). Similar studies are warranted, 
since long-term morbidity and disability after ARDS has been reported (Herridge 
et al. 2003).
 Physiological parameters are frequently used in clinical studies, but they have 
proven to be poor surrogates as long-term outcome predictors in ALI. In a large 
multicentre study evaluating the use of inhaled nitric oxide, improved oxygenation 
was not translated to better outcome (Lundin et al. 1999). Similar observations 
of improved oxygenation without outcome benefit include studies on exogenous 
surfactant (Spragg et al. 2004) and prone position (Gattinoni et al. 2001). In contrast, 
in the ARDSNet study of tidal volumes, worse oxygenation and higher carbon-
dioxide partial pressure was seen in the acute stage of treatment, but finally, all 
outcome parameters were significantly better in the group of lower tidal volume (6 
ml/kg) in comparison with traditional tidal volume (12 ml/kg) (ARDSNet 2000). 
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3 AIMS OF THE STUDY
The objective of this study was to evaluate the incidence, the treatment, and the 
outcome of acute respiratory failure in Finland, with special interest in the use of 
biomarkers in the prediction of outcome and the multi organ dysfunction. The aims 
in detail were as follows: 
1. To evaluate the incidence, the treatment, and the outcome of acute respiratory 
failure (ARF) in patients who were treated in Finnish intensive care units (I).
2. To investigate the levels of aminoterminal pro-brain natriuretic peptide (NT-pro-
BNP) (II) and plasma cell-free DNA (III) in ARF patients, with special interest in 
their prognostic value.
3. To study the collagen synthesis and degradation and their association with 
multiple organ dysfunction in ARF patients with prolonged hospital stay. (IV)
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4 PATIENTS AND METHODS 
4.1. patIeNtS 
This study consists of 958 adult patients in 25 ICUs who were treated with either 
invasive or non-invasive ventilatory support for at least six hours. All 958 patients 
took part in Study I. In studies II-IV patients with laboratory samples drawn for 
analysis of NT-pro-BNP (Study II), plasma cell-free DNA (Study III), and markers 
of collagen synthesis and degradation (Study IV) were evaluated. Patients included 
in studies I-IV are presented in Figure 2. The characteristics of patients included 
in Studies I-IV are presented in Table 6.
Figure 2. patients included in studies I-Iv 
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table 6. characteristics of patients included in studies I-Iv. 
Study I Study II Study III Study Iv
patient number 958 602 580 68
age 63 (51 – 74) 64 (53 – 75) 65 (53 – 75) 60 (50 – 70)
gender, male (%) 637 (67) 398 (66) 382 (66) 50 (74)
emergency 824 (86) 502 (83) 481 (83) 63 (93)
Operative 375 (39) 232 (39) 229 (40) 18 (27)
apache II 23 (17 – 29) 23 (17 – 30) 23 (17 – 30) 23 (18 – 29)
SapS II 43 (31 – 55) 42 (29 – 55) 42 (30 - 55) 44 (34 – 54)
SOFa at 24 h 8 (6 – 10) 8 (5 – 10) 8 (5 – 10) 9 (5 – 10) 
worst paO2/FiO2 
(first 3 days), mmhg 171 (118 – 234) 176 (123 -236) 176 (124 – 236) 150 (110 – 209)
ventilatory support time, days 2 (1 – 4) 2 (1 – 4) 2 (1 – 4) 8 (4 – 17)
IcU length of stay, days 3 (2 – 7) 3 (2 – 7) 3 (2 – 7) 11 (6 – 23)
hospital length of stay, day 11 (6 – 21) 12 (6 – 21) 12 (6 – 21) 38 (26 – 52)
IcU mortality, n (%) 120 (13) 63 (11) 61 (11) 1 (2)
hospital mortality, n (%) 230 (24) 138 (23) 134 (23) 6 (9)
90-day mortality, n (%) 295 (31) 174 (29) 169 (29) 8 (12)
Data are presented as median with interquartile range (IQR) or number and percentage (%).
4.2. StUDy DeSIgNS 
This study was a prospective cohort study conducted in Finnish intensive care units 
in 2007. All 27 ICUs were invited to participate in the study and 25 units consented. 
During an eight week period from April 16th to June 10th, all consecutive adult (≥16 
years) patients admitted to participating ICUs were screened for acute respiratory 
failure. Blood samples at four time points, at study admission (day 0) and at days 
2, 7, and 21, were drawn if the patient was still hospitalised. The ethical committee 
of the Surgical Department in Helsinki University Central Hospital approved the 
study. Written informed consent was not required for data registration, but only 
for blood sampling.
Study I
Study I is a description of the whole cohort. All periods of respiratory support were 
screened and the reason for support lasting less than six hours was recorded. The 
exclusion criteria were being aged under 16 years and the need for permanent 
ventilatory assistance. The patients’ social security number was used for mortality 
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assessment and in the combining of the data of the related periods in the separate 
ICUs. Only the first period of ARF was counted for incidence calculations. The adult 
population (≥16 years) count in Finland at the end of year 2006 was obtained from 
Statistics Finland (http://www.stat.fi). The adult population of hospital districts 
of two ICUs not participating in the study was attained from the Association of 
Finnish Local and Regional Authorities (http://kunnat.net) and subtracted. In the 
data processing and analysis, a unique ID number was used. 
Study II
Study II is a substudy of study I. The primary aim was to evaluate the prognostic 
value of NT-pro-BNP according to 90-day mortality in an unselected cohort of acute 
respiratory failure patients. Samples were analysed in 602 patients at baseline (day 
0) and in 505 patients on day 2. 
Study III
In study III, also a substudy of study I, the levels of plasma cell-free DNA and their 
potential in the prediction of outcome in ARF patients were investigated. Plasma 
samples were drawn from 580 patients at baseline (day 0) and in 489 patients on 
day 2.
Study IV
In study IV, we aimed to evaluate the change in the markers of collagen metabolism 
over time. Thus, only patients with serial blood samples from at least three time 
points (on days 0 and/or 2, 7 and 21) were included in this study. The association 
of collagen metabolism and multi organ dysfunction was also investigated. Patients 
were divided into groups according to the presence of MOD during the first week. 
A patient was defined to have MOD if the organ specific SOFA score of at least two 
organs was 3 or 4 on at least one day (Vincent et al. 2002). PINP and PIIINP were 
analysed as markers of collagen synthesis. ICTP was analysed as a marker of collagen 
I degradation. The ratio of PIIINP and PINP (PIIINP/PINP) was used to describe 
the relationship of the synthesis of two collagens with different temporal evolution. 
The ratio of PINP and ICTP (PINP/ICTP) was used to describe the relationship of 
type I collagen synthesis and degradation.
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4.3. clINIcal Data
All 25 participating ICUs belonged to the Finnish Intensive Care Quality Consortium 
(Intensium®), which collects intensive-care data for benchmarking purposes. Data 
collection was accomplished with the clinical report form (CRF), which acted as 
a supplement to the routine consortium dataset. The routine consortium dataset 
includes the reason for ICU admission, outcome measures, and severity scorings 
[Acute Physiology and Chronic Health evaluation (APACHE) II (Knaus et al. 1985), 
Simplified Acute Physiology Score (SAPS) II (Le Gall et al. 1993) and Sequential 
Organ Failure Assessment (SOFA) score (Vincent et al. 1996)]. The CRF data 
included patient demographics, underlying risk factors for ARF, physiological and 
ventilatory data, and medications. The survival data were obtained from Statistics 
Finland (www.stat.fi). The CRF data were collected at study admission, once daily 
during the intensive care, and at discharge from the ICU. An internet-based interface 
was utilized to enter the routinely-collected data, and the CRF data was attached as 
an additional file. All of the data was stored in the ICU quality database.
4.4. meaSUremeNtS OF BIOmarkerS
After written consent from the patient or the next of kin, blood samples were drawn 
from an arterial line. A 10 ml plasma sample collected to a heparin tube, in addition 
to a 10 ml serum sample collected to a regular tube, was obtained at days 0 (study 
admission), 2, 7, and 21, if patient was still hospitalised. Samples were centrifuged 
3100 rpm (~ 1500 g) for 15 minutes as soon as possible, after which plasma and 
serum were stored in each hospital at -20 ºC or lower. After the study end, all 
samples were collected to Helsinki University Central Hospital and stored at -80 
ºC before subsequent analyses.
4.4.1 Nt-prO-BNp
Plasma NT-pro-BNP concentrations were determined after the first thaw using 
a commercial immunoassay (Elecsys proBNP, Roche Diagnostics, Mannheim, 
Germany) on an Elecsys 2010 automatic analyzer (Roche Diagnostics, Mannheim, 
Germany). Two-fold dilution was accomplished if the result was above upper range 
(35 000 pg/ml). If the result was above 70 000 pg/ml, the further dilution was 
abandoned due to larger deviations in values after dilution and minor information 
achieved. All laboratory analyses were performed in a single accredited laboratory 
(Helsinki University Central Hospital Laboratory, HUSLAB). 
45
4.4.2 plaSma cell-Free DNa
The extraction of DNA and the quantification of plasma cell-free DNA was performed 
according to a method described earlier (Saukkonen et al. 2008, Saukkonen et al. 
2007). Plasma samples were first centrifuged at 16 000 g for 10 min to remove 
any residual cells (Swinkels et al. 2003). DNA was extracted using the QIAamp 
DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the “blood and body 
fluid protocol”. The measurement of plasma cell-free DNA was accomplished by 
real-time quantitative PCR assay for the β-globin gene. A 10-fold serial dilution 
of human genomic DNA (Roche, Mannheim, Germany) was used as a standard 
curve in the PCR assay. Results are expressed as genome equivalents (GE)/ml; 1 
GE equals 6.6 picograms of DNA.
4.4.3 markerS OF cOllageN metaBOlISm
Analyses of serum PINP, PIIINP, and ICTP were achieved by radioimmunological 
assays (Orion Diagnostica, Espoo, Finland). Reference values for PIIINP are 1.7 - 4.2 
μg/L, for PINP 19 - 84 μg/L (women) and 20 - 76 μg/L (male), and for ICTP 1.6 
- 4.6 μg/L (Risteli et al. 2002). For serum intact PINP assay, the inter- and intra-
assay coefficients of variation (CV) were between 3.1 and 9.3% for values within 
the reference intervals (Melkko et al. 1996). For serum PIIINP assay, inter- and 
intra-assay CVs were from 3.0 to 7.2% for values ranging from 2.7 to 12.2 μg/L. The 
CVs of the ICTP method ranged from 3 to 8% for a wide range of concentrations 
(Risteli et al. 1993)
4.5. DISeaSe SeverIty ScOrINgS aND DeFINItIONS
The severity of disease at baseline was assessed by APACHE II (Knaus et al. 1985) 
and SAPS II (Le Gall et al. 1993) scores, which were calculated after 24 hours in 
the ICU. Sequential organ failure assessment (SOFA) score was calculated daily to 
define organ dysfunctions (Vincent et al. 1996). Multiple organ dysfunction (MOD) 
was defined as a SOFA score of 3-4 for at least two organs at the same time (Vincent 
et al. 2002) (IV). Acute lung injury (ALI) and acute respiratory distress syndrome 
(ARDS) were defined according to AECC consensus criteria (Bernard et al. 1994). 
The infection status was defined according to APACHE III, ICD-10 diagnoses, and 
underlying risk factors (pneumonia or sepsis during preceding 48 hours) (III).
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4.6. OUtcOme
The mortality at 90-days was reported as long-term outcome measure (I-III). As 
short-term outcome parameters, ICU and hospital mortalities were reported (I-IV).
4.7. StatIStIcal methODS
Data are presented in absolute numbers and percentages, in medians with 
interquartile ranges (25th and 75th percentiles, IQR), or means and standards 
deviations (SD) as appropriate.
Statistical significance. A p-value < 0.05 was considered significant in all 
analysis (I-IV). An exception for this is where the plasma cell-free DNA levels were 
compared between different strata of oxygenation. In this circumstance, Kruskal-
Wallis test was used, and Mann-Whitney test in a post-hoc analysis, where p< 0.01 
was considered significant due to multiple comparisons (III).
Fisher’s exact test was used for comparisons of categorical data between groups 
(I, IV)
Kaplan-Meier survival curves of 90-day mortality were constructed according 
to quartiles of baseline NT-pro-BNP (II) and the best cut-off point of baseline plasma 
cell-free DNA (III). Log rank test was used for comparisons of different strata.
Kruskal-Wallis test was used for comparisons of multiple groups of continuous 
data (II-III)
Linear mixed model approach was used for the analyses of repeated 
measurements of fibrosis markers (IV).
Multivariate logistic regression analysis was used to evaluate the independent 
effect of variables on outcome (I-III).
Mann-Whitney U-test was used in the comparisons of continuous data between 
independent groups. It was used to compare demographic data (I-IV) and biomarker 
data (II and III).
Pearson’s χ²- test was used in the comparisons of categorical data (IV).
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Receiver operating characteristics (ROC) curve analysis was used to evaluate 
the prognostic value NT-pro-BNP and plasma cell-free DNA. The best cut-off values 
were identified by Youden method (Youden 1950), and the sensitivity, specificity, 
positive likelihood ratio (II and III), and positive and negative predictive values (II) 
for baseline NT-pro-BNP and cell-free DNA were calculated for it. 
The area under ROC curve (AUC) was calculated with 95% confidential 
intervals (II, III). 
Student’s t-test was used for the comparisons of normally distributed continuous 
variables (IV).
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5 RESULTS
5.1. the INcIDeNce OF arF, alI aND arDS IN FINlaND
During an eight week study period, 2670 patients were admitted to ICUs participating 
the study, and ventilatory support was accomplished in 1319 (49.4%) of admissions. 
In 273 (20.7%) of ventilatory support periods, treatment continued for less than 
six hours. After exclusion of these short treatment periods, multiple admissions, 
foreign citizens, and periods with incomplete data, there were 958 patients, who 
were treated for more than six hours with either invasive or non-invasive ventilatory 
support. The incidence of ARF, estimated from the incidence in the study period, 
was 149.5 / 100 000 inhabitants per one year. The incidence of ARF patients with 
ventilatory support for more than 24 hours was 102.7 / 100 000 per year. Of 958 
patients, all criteria of ALI were fulfilled in 68 patients and those of ARDS in 32 
patients. The incidence of ALI and ARDS defined by AECC criteria were 10.6 and 
5.0 / 100 000 per year. 
5.2. veNtIlatOry treatmeNt
The majority of patients (775 of 958, 81%) were invasively ventilated from the start. 
During the treatment, 78 more patients were intubated, and 105 (11%) were treated 
only with non-invasive methods. At baseline, pressure controlled modes were used in 
43% and volume controlled in 47% of cases. Modes allowing spontaneous triggering 
were used in 81%, while entirely controlled modes only in 9%. 
 The median (IQR) tidal volume at baseline was 7.4 (6.2 – 8.7) (ml/kg ABW) and 
8.7 (7.6 – 9.9) (ml/kg PBW) in non-ALI/ARDS patients, and 7.5 (6.3 – 9.0) (ml/
kg ABW) and 8.6 (7.3 – 9.9) (ml/kg PBW) in ALI/ARDS patients, p = NS. Plateau 
pressures in non-ALI/ARDS and ALI/ARDS patients were 19 (16 – 23) cmH2O and 
23 (18 – 27) cmH2O, respectively, p < 0.05. The median PEEP level was 6 (5 – 8) 
cmH2O in non-ALI/ARDS group and 8 (6 – 10) cmH2O in ALI/ARDS group (p = 
0.001), respectively.  
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5.3. Nt-prO-BNp aND cell-Free DNa IN arF patIeNtS
Higher than normal (>125 pg/ml) NT-pro-BNP values were detected in 88 % (529 
of 602) of study patients at baseline. Baseline levels were significantly higher in 90-
day non-survivors than survivors, median (IQR) 4378 pg/ml (1400 – 13943 pg/ml) 
versus 1052 pg/ml (232 – 4076 pg/ml) (p < 0.001), and the difference remained 
significant for sample B on day 2, 3458 pg/ml (865 – 11875 pg/ml) versus 1613 
pg/ml (359 – 3891 pg/ml) (p < 0.001), respectively. 
 NT-pro-BNP levels at baseline according to baseline levels of arterial oxygen 
pressure are presented in Figure 3. The difference between groups was significant, 
p < 0.001 (Kruskal-Wallis for all groups). Baseline NT-pro-BNP values in patients 
with normal renal function were significantly higher with chronic cardiac disease or 
cardiac surgery when compared to non-cardiac patients (p < 0.001). The levels of 
NT-pro-BNP increased significantly with deteriorating renal function in all patients 
(p < 0.001 for both cardiac and non-cardiac patients). 
Figure 3. Baseline levels of arterial oxygen pressure (paO2) according to quartiles of baseline 
plasma N-terminal pro-brain natriuretic peptide (Nt-pro-BNp).
50
Results
Plasma cell-free DNA levels were significantly higher in 90-day non-survivors than 
survivors, median 16 636 GE/ml (IQR 7262 – 46 866 GE/ml) versus 10 026 GE/
ml (4870 – 19 820 GE/ml), respectively (p < 0.001). The median (IQR) baseline 
DNA concentration in postoperative patients was 11 436 GE/ml (5587 – 20 379 
GE/ml), and in non-operative patients 12 156 GE/ml (4938 – 27 292 GE/ml), p 
= 0.36. Plasma DNA at admission correlated with the baseline PaO2/FiO2-ratio, p 
< 0.001) . Figure 4 presents baseline plasma DNA according to quartiles of PaO2/
FiO2-ratio (p < 0.001, Kruskal-Wallis for groups).
Figure 4. plasma baseline cell-free DNa according to quartiles of paO2/FiO2-ratio
The ROC-curves of baseline NT-pro-BNP and plasma cell-free DNA for the 90-day 
mortality prediction are presented in Figure 5. The best cutoff value for NT-pro-BNP 
at baseline was 1765 pg/ml. Its sensitivity for 90-day mortality was 73% (95% CI, 
66 – 79%), with a specificity of 63% (95% CI, 58 – 67%), a negative predictive value 
of 85% (95% CI, 81– 89%), a positive predictive value of 44% (95% CI, 39 – 50%), 
and a positive likelihood ratio of 1.965 (95% CI, 1.686 – 2.289). The best cut-off 
value for baseline plasma cell-free DNA obtained from the ROC-curve analysis, 
was 16 000 GE/ml, with a sensitivity of 53% (95% CI 45 – 60%), a specificity 69% 
(65 – 74%), and a positive likelihood ratio of 1.72 (1.4 – 2.11). The odds ratio of 
plasma cell-free DNA being over cut-off value was 2.22 (1.41 – 3.48) for 90-day 
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mortality. The AUC of NT-pro-BNP levels at baseline was 0.718 (95% CI 0.674 – 
0.761) and that of plasma cell-free DNA 0.624 (95% CI 0.572 – 0-676).  
Figure 5. rOc curves of plasma baseline N-terminal pro-brain natriuretic peptide (Nt-pro-
BNp) and cell-free DNa for predicting 90-day mortality
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5.4. prOgNOStIc valUe OF cOmBININg plaSma Nt-prO-
BNp aND cell-Free DNa 
A significant correlation between NT-pro-BNP and cell-free DNA values was noticed 
at baseline, ρ 0.301, p < 0.001 (Figure 6). 
Figure 6. plasma N-terminal pro-brain natriuretic peptide (Nt-pro-BNp) values at baseline 
plotted against plasma cell-free DNa values at baseline. the picture in the upper left corner 
presents all values, and the picture in the low right corner a subset of values cropped from 
the upper picture.
The Kaplan-Meier survival curves for 90-day mortality in patients with baseline 
NT-pro-BNP and plasma DNA values over or below separate cut-off levels are 
presented in Figure 7. Survival was significantly different in patients with both 
markers being over cut-off levels (n=132), only NT-pro-BNP (n=146) or plasma 
DNA (n=83) being over cut-off, or both markers (n=219) being below cut-off levels 
(p < 0.001 log rank test for all curves).
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Figure 7. kaplan-meier survival curves for 90-day mortality according to both N-terminal pro-
brain natriuretic peptide (Nt-pro-BNp) and cell-free DNa values being over or under cut-off 
A multiple logistic regression analysis was accomplished with the inclusion of the 
following factors: baseline NT-pro-BNP over best cut-off (1795 ng/ml), baseline 
plasma cell-free DNA over best cut-off (16 000 GE/ml), infection status, baseline 
PaO2/FiO2-ratio, chronic heart disease, underlying risk factors for ARF (acute 
heart insufficiency, intoxication, and suspected aspiration), SAPS II score minus 
oxygenation, and SOFA score at 24 hours. The independent predictors of 90-day 
mortality were baseline NT-pro-BNP over cut-off (p < 0.001), baseline plasma 
cell-free DNA over cut-off  (p = 0.004), baseline PaO2/FiO2-ratio (p = 0.023), and 
SAPS II score minus oxygenation (p< 0.001). 
5.5. SerUm markerS OF cOllageN metaBOlISm
Study patients (n=68) were on average 60 years old (SD 15, range 20-86), 50 
(74%) were male, and 18 (26%) were postoperative patients. Thirteen (19%) patients 
fulfilled the criteria for ALI or ARDS, and 43 (63%) for MOD. SAPS II points ranged 
from 2 to 83 (mean 45, SD 15) and SOFA score at 24 hours from 2 to 17 (mean 9, 
SD 3). The mean (SD, range) ventilatory support time was 12 (11, 1-46) days, ICU 
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length of stay 15 (13, 1-60) days, and hospital length of stay 44 (20, 18-116) days. 
Patients in the cohort were more often admitted for operative reasons than the 
rest of the FINNALI study patients (p = 0.026). The ventilatory support time (p < 
0.001), and length of stay in ICU and hospitals were significantly longer (p < 0.001 
for both), but the severity of illness was equal, as measured by SAPS II score, and 
SOFA at 24 hours (p = 0.36 and p = 0.43, respectively).   
 PIIINP values increased over time in all patients in the cohort (p < 0.001), and 
the increase was more pronounced in patients with MOD (p = 0.026). The change in 
PINP levels over time was significant (p < 0.001), but did not differ between patients 
with MOD or without it (p = 0.74). ICTP levels showed a significant increase in all 
patients, but the levels in patients with MOD and without it were comparable (p 
= 0.16). In the maximum values of PIIINP, PINP, and ICTP during the first week, 
there was no difference between MOD and non-MOD patients.
 Table 7 presents the levels of NT-pro-BNP and cell-free DNA in the collagen 
cohort patients in comparison to others. No differences in the levels were noticed 
between these groups.
table 7. plasma N-terminal pro-brain natriuretic peptide (Nt-pro-BNp) and cell-free DNa 
values in patients with both markers measured; a comparison between patients in collagen 
cohort and other patients. values are presented in median (IQr).
Patients in the collagen 
cohort
Other patients with NT-
pro-BNP and cell-free 
DNA samples
p-value 
(Mann-Whitney)
Number 56 524
NT-pro-BNP 
at baseline 1646 (296 – 6438) 1626 (348 – 6423) 0.91
at day 2 1874 (283 – 8251) 1882 (539 – 4869) 0.68
Plasma cell-
free DNA 
at baseline 14 540 (6490 – 27 556) 11 578 (5199 – 24 198) 0.20
at day 2 13 370 (6982 – 25 623) 11 540 (6348 – 20 308) 0.26
5.6. OUtcOme
The overall mortality at 90-days was 31% (95% CI 28-34%). In a subgroup of patients 
with ventilatory support more than 24 hours, 90-day mortality was 32% (95% CI 
29-36%) and in ALI/ARDS patients 47% (95% CI 35-59%). In patients with a failure 
of non-invasive ventilatory support, the mortality rate was 49%. Patient mortality 
at 30 days in study IV was 4% (3 of 68).
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6 DISCUSSION 
Incidence
The incidence of acute respiratory failure reported here is much higher than 
reported earlier (Lewandowski et al. 1995, Luhr et al. 1999). The most obvious 
reason for this is the wider definition used in this study. Although one earlier study 
has reported an ARF incidence of 137 / 100 000, which is closer to that of the 
present study, the definition used in that study was completely different (Bersten 
et al. 2002). Nonetheless, the incidence in the present study remained high, even 
after correction of the ARF definition to 24 hours of respiratory support. Other 
plausible explanations include differences in admission policies and organizational 
factors. In many European countries, specific respiratory ICUs and intermediate 
care units exist (Corrado et al. 2002, Polverino et al. 2010). In Finland, however, 
intermediate care units are uncommon, and, thus, patients needing ventilatory 
support are commonly admitted to ICU. Additionally, the differences in health 
care systems may partly explain these results, especially in comparison to north 
American studies. The incidence of ALI/ARDS observed, on the contrary, was lower 
than in some other studies (Bersten et al. 2002, Rubenfeld et al. 2005) but still at 
the same level as in an earlier report from Finland (Valta et al. 1999). The difference 
in ALI and ARDS incidence remains unexplained, but factors mentioned above, 
most probably have some impact. Genetic variation for susceptibility may also partly 
explain this variation (Marshall et al. 2002). 
Ventilatory modes and settings
The proportions of ventilatory modes used at baseline, resemble those reported in 
a 1-day point prevalence study in Nordic countries (Karason et al. 2002). In the 
present study, the use of pressure-controlled modes was clearly more popular than 
in most countries outside Scandinavia (Esteban et al. 2008). 
 In Finnish ICUs, the lung protective ventilatory strategy has been adopted only 
partially, the result being uniform with earlier reports (Weinert et al. 2003, Young 
et al. 2004). A steady increase in a proportion of tidal volumes less than 6.5 ml/
kg PBW has been reported previously, but the proportion was still around 40% of 
patients in 2005 (Checkley et al. 2008). The tidal volumes in the present study were 
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higher than recommended, especially when calculated per predicted body weight 
instead of actual body weight. The difference in tidal volumes between PBW and 
ABW was larger in women than in men, as reported previously (Gajic et al. 2004), 
which has an important clinical significance. The size of the lungs is determined 
by gender and height and these factors should primarily impact the tidal volume 
setting, a fact that is often forgotten in clinical practise. The limitation of inspiratory 
pressure was, however, much better implemented.
NT-pro-BNP and cell-free DNA in ARF patients
Both of the evaluated biomarkers were commonly increased in critically ill patients 
with acute respiratory failure. The levels of NT-pro-BNP were elevated in the great 
majority of the ARF patients, which is in accordance with earlier studies reporting 
great increases in NT-pro-BNP levels in ARF and ARDS patients (Bajwa et al. 
2008). The present study differs from earlier studies in the patient population, but 
the results are basically comparable. Reference values for plasma cell-free DNA do 
not exist, but the levels in this study were high when compared to normal controls 
in meta-analysis (van der Vaart et al. 2010). When comparing to earlier studies, 
our results are essentially in accordance. Because of variations in method, however, 
direct comparisons cannot be done. 
 Cut-off values of NT-pro-BNP for best mortality prediction have ranged from 
940 pg/ml in an unselected, non-cardiac ICU patient population, to 6800 pg/ml 
in ARDS patients, and 7090 pg/ml in patients with severe sepsis and septic shock 
(Varpula et al. 2007, Bajwa et al. 2008). The best cut-off value in the present study 
was 1765 pg/ml, in comparison to a previous study of 78 ICU patients (with an 
APACHE II score over 12) that had a level of 1900 pg/ml (Almog et al. 2006). The 
AUC for baseline NT-pro-BNP for the prediction of 90-day mortality in this study 
was 0.718. This result is in accordance with earlier studies in ARDS (Bajwa et al. 
2008, Kotanidou et al. 2009).  
 The exact mechanism by which NT-pro-BNP is elevated in ARF patients is 
not known. Myocardial function, and thus the release of NT-pro-BNP, may be 
affected by acute respiratory failure and subsequent ventilatory treatment in several 
mechanisms. Theoretically, increased NT-pro-BNP could serve as a marker of fluid 
overload. Earlier studies, however, have shown that NT-pro-BNP levels are not 
able to distinguish between cardiogenic pulmonary oedema and ALI (Levitt et al. 
2008) and do not associate with pulmonary artery occlusion pressure in critically 
ill patients (Jefic et al. 2005, Tung et al. 2004). The results of the present study 
are in accordance, since no correlation between baseline NT-pro-BNP and central 
venous pressure (CVP) or pulmonary artery occlusion pressure (PAOP) was noticed. 
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Furthermore, filling pressures do not necessarily correlate with cardiac preload in 
critically ill patients, a result reported in mechanically ventilated sepsis patients 
(Osman et al. 2007). The relationship between NT-pro-BNP and the elevation of 
intrathoracic and transpulmonary pressures induced by positive pressure ventilation 
remains unresolved. 
 NT-pro-BNP levels have been reported to increase in patients with renal 
insufficiency (Forfia et al. 2005b) and the results of this study are compatible. 
NT-pro-BNP values showed a clear tendency to increase with deteriorating renal 
function whether the patient had a cardiac condition or not. In many critically ill 
patients, the significance of NT-pro-BNP measurements is, thus, diminished.
 An interesting issue is the possible role of myocardial hypoxia. Hypoxemia has 
been shown to stimulate the secretion of BNP in an animal study on piglets (Khan 
et al. 2008). Additionally, hypoxia has been shown to directly induce BNP release 
from human myocytes in patients with cyanotic congenital heart disease (Hopkins 
et al. 2004). BNP has also recently been shown to be able to detect silent myocardial 
ischemia in diabetic patients without heart insufficiency (Rana et al. 2006). Based on 
recent data, the role of hypoxia has been emphasized in the regulation of natriuretic 
peptides (Arjamaa et al. 2011). The results of the present study are in accordance with 
this hypothesis, since the baseline NT-pro-BNP levels increased with the lowering 
arterial oxygen pressure, although the median levels were not hypoxemic. The level 
of tissue hypoxia, however, was not measured in this study. In critically ill patients, 
especially in septic patients, the oxygen utilizing capacity of tissues, resulting from 
the deteriorated microcirculation, is known to decrease, resulting in lactatemia and 
risk of organ dysfunction (Levy et al. 2005). 
 BNP release has also been shown to be stimulated by proinflammatory cytokines 
(Ma et al. 2004) and several neurohormones (adrenergic agonists, endothelin, and 
ATII) (Mair 2008). Theoretically, these factors may have played a role in our study 
population and partly explain the increased concentrations of NT-pro-BNP. 
 A range of different methods used in the quantification of cell-free DNA in 
earlier reports makes it difficult to make direct comparisons between studies. 
These differences most probably play role in some studies with highly differing 
concentrations (Kocsis et al. 2009). The levels of plasma cell-free DNA in this study, 
in general, are situated in the middle of those reported previously (Rhodes et al. 
2006, Saukkonen et al. 2008, Saukkonen et al. 2007). In non-operative patients, 
baseline plasma DNA levels were higher in those with infection, consistent with 
published results (Rhodes et al. 2006, Saukkonen et al. 2007). In operative patients, 
the levels did not differ, although there was a tendency (p = 0.053) towards it. 
Operative patients presented with less severe illness, as measured by SAPS II score, 
but had similar levels of plasma DNA in comparison to non-operative patients. This 
result suggests that surgery, per se, may have raised the levels. This hypothesis is 
58
Discussion
supported by the rising plasma DNA in operative, but not non-operative patients. 
 The prognostic value of plasma DNA was not particularly good in this study. 
The AUC was 0.643 for the 90-day mortality prediction in all patients in the cohort, 
somewhat lower than previous studies. None of the subgroups presented with better 
values. When examining the earlier reports of  plasma DNA in critically ill patients, 
it is obvious that AUC is better when tested on short period survival, but shows a 
tendency to lower when longer outcome periods are employed (Rhodes et al. 2006, 
Saukkonen et al. 2008). In this context, the result of the present study is consistent.
 The exact origin of plasma cell-free DNA in this study remains unclear. 
Theoretically, possible options in ARF include apoptotic neutrophils, alveolar 
epithelial cells, and myofibroblasts, but also remote organ cells. Furthermore, unlike 
in healthy humans, cell necrosis associated with inflammation is probable. A first 
successful attempt to characterize circulating DNA in cancer and control patients 
was made recently, where a differentiation between groups could be shown (van 
der Vaart et al. 2008). Tissue hypoxia is one tempting reason for increased plasma 
DNA levels, supported by a recent report in patients with mesenterial ischemia 
(Arnalich et al. 2010a). The higher concentrations in patients with infection support 
this hypothesis, considering the metabolic consequences of sepsis at the tissue level, 
as indicated earlier with NT-pro-BNP. Unfortunately, however, the tissue hypoxia 
parameter, lactate, was not measured in this study. Correlation with plasma DNA 
and pH at baseline was noticed, a finding possibly reflecting anaerobic metabolism 
at the tissue level. Nonetheless, due to observational nature of this study, these 
speculations remain purely hypothetical.
Prognostic value of combining plasma NT-pro-BNP and cell-free DNA
A correlation between baseline levels of NT-pro-BNP and plasma cell-free DNA 
was found, but it was rather weak, revealed also by visual inspection (Figure 6). 
Contrary to this, in a recent small study, no correlation between plasma DNA and 
NT-pro-BNP was noticed (Rhodes et al. 2006).
 In a logistic regression analysis including both markers as categorical variables, 
they remained independent predictors of outcome, suggesting a role separate 
from the severity of illness. PaO2/FiO2-ratio was also an independent predictor 
in the multivariate analysis of study I without any biomarkers included in the 
analysis. Earlier studies have shown differing results concerning PaO2/FiO2-ratio 
as a prognostic factor in ALI and ARDS patients. Measured at baseline, it has not 
been an independent predictor of death, although it may have been associated with 
death in univariate analysis (Brun-Buisson et al. 2004). The other factors remaining 
significant in multivariate analysis were SAPS II score minus oxygenation points, 
59
SOFA score at 24 hours, infection status, and chronic heart disease, the result being 
in accordance with earlier studies. SAPS II, in particular, has been frequently found 
to independently predict mortality in ALI/ARDS patients (Brun-Buisson et al. 2004, 
Monchi et al. 1998, Nuckton et al. 2002). In addition, chronic diseases, sepsis, and 
organ dysfunctions have been reported to be prognostic factors (Brun-Buisson et 
al. 2004, Doyle et al. 1995, Zilberberg et al. 1998).
 A significant difference in survival was noticed, when both biomarkers were 
used in combination (Figure 7), consistent with a recent study evaluating the use 
of several biomarkers in combination for the diagnosis of ALI in trauma patients 
(Fremont et al. 2010). In that retrospective analysis, 107 trauma patients fulfilling 
AECC criteria for ALI/ARDS during their first three days after admission were 
compared to 85 patients without ALI over seven days. From 21 biomarkers measured, 
7 markers representing epithelial and endothelial injury, collagen deposition, cardiac 
dysfunction, and inflammation, were selected to form a biomarker panel. Using this 
panel for diagnosis of ALI/ARDS, the AUC was 0.86 (95% CI 0.82-0.92). Restricting 
the number of biomarkers in the panel to three best performing (RAGE, procollagen 
propeptide III and BNP), the AUC was almost at the same level, 0.83 with 95% CI 
0.76-0.88. Patients with a high probability of ALI/ARDS, according to the panel, 
spent more days in the ventilator and in ICU when compared to patients with a 
low probability of ALI/ARDS. The hospital mortality did not differ between groups, 
18% in high and 6% in low probability group, but the study was most probably 
underpowered for the prediction of mortality. Another recent study showed similar 
results for predicting the mortality of ALI/ARDS patients with several biomarkers 
(Ware et al. 2010). This study was based on a patient cohort of an earlier prospective 
study of 549 patients, where low versus high levels of PEEP were evaluated (Brower 
et al. 2004). Ware and colleagues observed that a combination of six clinical risk 
factors and eight biomarkers was superior in mortality prediction with AUC 0.85 
(95% CI 0.813 – 0.833). A reduced model with two clinical risk factors (APACHE 
III score and age) and two biomarkers (SP-D and IL-8), showed almost as good 
predictive power with AUC 0.834 (95% CI 0.789 – 0.862). 
Markers of collagen metabolism
This was the first study to report the levels and the evolution of markers of collagen 
metabolism in patients with ARF. Earlier studies in ARDS patients have found 
procollagen III levels to increase early in the course of disease and the results of 
this study were comparable (Marshall et al. 2000, Meduri et al. 1998). In ARDS 
patients, increase in PINP and PIIINP over time has been reported, in accordance 
with the results of the present study (Meduri et al. 1998). PINP levels, although 
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tending to increase, remained practically inside reference values. A similar result 
has been reported in severe sepsis patients (Gaddnas et al. 2009). The ratio of 
PIIINP and PINP increased early, followed by a later decrease back to baseline. 
This suggests that the collagen profile changes to a more stable and less deformable 
composition over time, a novel finding in this study. ICTP levels also showed an 
increase over time, that when accompanied with an initial decrease in the ratio of 
PINP and ICTP, this suggests degradation of collagen type I during the acute phase 
of ARF. High ICTP levels have been previously reported in patients with trauma 
and severe sepsis (Gaddnas et al. 2009, Waydhas et al. 1993).
 Whether patients suffered from multiple organ dysfunction or not, maximum 
levels of serum markers of collagen metabolism did not differ. This is inconsistent 
with a previous report in sepsis patients (Gaddnas et al. 2009). The highly 
selected patient population in the present study is most probably a reason for 
this discrepancy. Only patients with serial blood samples extending to day 21 were 
included. Inevitably, this excluded the most severely ill patients, who did not survive 
until day 21. For the same reason, the mortality of study patients was extremely 
low, and precludes prognostic analyses. 
 Due to small patient numbers, subgroup analyses concerning operative status 
and the use of corticosteroids were not rational. These factors, however, may have an 
effect on procollagen levels. Procollagens measured from plasma have been shown to 
increase early in lung injury, correlating with outcome (Meduri et al. 1998). In this 
small landmark study of Meduri and colleagues, treatment with methylprednisolone 
resulted in the decrease of procollagen levels and increased survival. Furthermore, 
in a small clinical trial where corticosteroid treatment was started 10 days after the 
primary insult in ALI patients, better oxygenation was seen in the steroid group, but 
no difference in mortality nor adverse effects (Varpula et al. 2000). More recently, 
the results of a large scale RCT with 180 patients have been reported (Steinberg et 
al. 2006). In that study, patients in the methylprednisolone group had improved 
oxygenation and lung compliance, and fewer days in ventilator, but also higher 
rate of recurrent respiratory failure and no difference in mortality. Corticosteroid 
treatment was started, however, not until one to four weeks after the diagnosis of 
ARDS, possibly too late in the light of studies showing collagen synthesis to start very 
early after primary insult (Marshall et al. 2000). Of special interest, in a post-hoc 
analysis, patients treated with steroids and having higher levels of procollagen III at 
baseline, experienced better survival, in contrast with patients with low procollagen 
III levels, in whom steroid treatment associated with higher mortality. This result 
supports the wider employment of individually customised treatment for which 
biomarkers are one tool that may guide clinical decisions.
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Outcome
The overall mortality at 90-days was 31%, which is slightly lower than in earlier 
studies in ARF patients (Behrendt 2000, Luhr et al. 1999), thus the implementation 
of lung protective ventilatory strategy may impact clinical outcome. On the other 
hand, mortality in ALI and ARDS patients was higher than in some randomized 
trials but comparable to recent pooled mortality in observational studies (Phua et 
al. 2009). It is worth noting that in multicentre studies, only Luhr and colleagues 
have reported 90-day mortality previously, the same end point that has been utilised 
in the present study. 
Strengths and limitation of the study
The unquestionable strength of this study is a large and nationally comprehensive 
patient material. All intensive care units, except two units from small central 
hospitals, participated in this study. The coverage of 25 participating units represents 
97% of the adult population in Finland. Thus, the generalisation of the results can 
be considered quite good in the group of critically ill ARF patients. However, the 
study has several points that need to be discussed. First, the group of ARF patients 
is heterogeneous due to numerous diseases able to cause respiratory failure. ARF 
does not have any standard definition, and thus the definition used in the present 
study is also arbitrary and can be criticised. All patients needing respiratory support, 
invasive or non-invasive, for at least six hours were included. The time frame has 
been longer in earlier studies, 24 hours in most cases, and only patients with invasive 
ventilation had been included (Flaatten et al. 2003, Luhr et al. 1999). However, 
in order to evaluate prognostic laboratory markers (Studies II and III), it is logical 
to collect the samples as near the insult as possible. The exact time of an insult 
leading to acute respiratory failure, is in most cases impossible to determine. The 
time elapsing from insult to sampling is, thus, imprecise and variable. Ventilatory 
support itself can also be considered an insult, therefore, minimizing the time of 
ventilatory support is rational in this context. Furthermore, excluding non-invasively 
treated ARF patients from the study would not have been sensible, since they clearly 
form a subgroup of ARF patients. Non-invasive ventilatory support has been used 
increasingly during previous years (Demoule et al. 2006) and has proven to be 
superior to invasive ventilation in selected groups of patients (Hilbert et al. 2001, 
Plant et al. 2000). Additionally, the results of the subgroup analyses with stricter 
ARF criteria, closer to the criteria of earlier studies, did not differ from the results 
of all patients strengthening the generalisation of the results.
 The patients included in studies II and III, and especially in study IV, represented 
only a subgroup of all patients. Patients were more often admitted for elective 
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surgery in studies II and III, which may impact the results. In subgroup analyses 
performed in studies II and III, the results did not change, although elective patients 
and patients with a ventilatory period of less than 24 hours were excluded. Patients 
in study IV were stringently selected in order to evaluate the development of fibrosis 
markers over time, which prevented reasonable analyses concerning outcome.
Ethical considerations 
The study was approved by the ethical committee of Helsinki University Central 
Hospital. Due to the observational nature of the study, based on an established 
standard of care, informed consent was required only for blood sampling. Blood 
sampling was accomplished via arterial line, which is an established part of the 
monitoring in intensive care units. All patients in this study were treated with 
respiratory support, most with invasive ventilation, and sedation that rendered them 
incapable of giving consent. Thus, after explaining study information verbally and 
in writing, a written consent was obtained from the next of kin. Given that the next 
of kin may be suffering some confusion during the acute situation, this approach 
could be seen as ethically vulnerable, but the negligible risk caused by the blood 
sampling attenuates it. 
Methodological considerations
This was a prospective cohort study, which is reasonable for evaluating the questions 
posed in this study. Some issues, however, need to be discussed. This study was 
prospective, but purely observational, and patient care was not standardised in 
anyway. Factors known to have effect on outcome have been taken into consideration 
in the statistical analyses, but many unknown factors may have had an impact on 
the results. Additionally, the observational nature of the study makes it impossible 
to confirm or refute any causalities. The challenge of a cohort study is to collect a 
patient population which would represent well the larger population. The size of 
the cohort should be large enough, both in number of patients, and in geographical 
coverage. In this study, the overall number of patients was sufficient, but numbers 
in subgroups, including ALI and ARDS, was considerably lower restricting the 
confirmative subgroup analyses. The geographical coverage was excellent and 
possible impact factors, such as associated genetic factors among others, can be 
considered minimal.
 The duration of the study period was eight weeks and the incidence calculations 
were based on that. Periodical change in the incidence is, thus, possible and can 
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be reflected to results. The occurrence of respiratory infections, in particular, is an 
important underlying condition for ARF, and is thought to show some seasonal 
variation. Indeed, the number of patients admitted to Finnish ICUs due to respiratory 
failure has been shown to be higher in the winter time (Reinikainen et al. 2006). 
The patient cohort in the present study was collected in the late spring time, so 
the possible bias would cause some underestimation of the incidence.  
The laboratory method used in the analysis of NT-pro-BNP was a routinely-used 
commercial method. All samples were collected to Helsinki and the analyses were 
performed in one laboratory (Helsinki University Central Hospital Laboratory, 
HUSLAB) by professional personnel. Standardised laboratory methods for plasma 
cell-free DNA extraction and determination were carried out by experienced 
laboratory personnel. The measurements of serum markers of collagen metabolism 
were accomplished by a specialised laboratory in Oulu University Hospital.  
Clinical implications and future perspectives
The results of this study are important in many aspects. First, the results of the 
incidence of ARF (I) offer valuable information regarding organizational planning, 
especially concerning the need for intensive care beds. Second, the ability of NT-
pro-BNP to differentiate between cardiac and non-cardiac reasons for respiratory 
failure is affected by renal failure, suggesting that this measurement has limited 
value in many critically ill patients. Third, either NT-pro-BNP or plasma cell-free 
DNA as single parameters, do not seem to work as prognostic tools in population 
of unselected ARF patients, but when used in combination, the value seems to be 
better. Finally, interesting results of increased collagen III synthesis in ARF are 
worth further studies.
 Since ALI is a multifactorial syndrome, with differences known to exist in the 
pathophysiology, and in the clinical picture according to predisposing conditions, 
it would seem rational to account for these differences somehow in future studies. 
Measurements of lung mechanics would be one solution to differentiate patients 
with different forms of ALI (Gattinoni et al. 1998). Standardized performance of 
these procedures may be challenging in a clinical setting, although new technology 
has been introduced recently for monitoring of ventilated lung areas (Frerichs et 
al. 2002) and functional residual capacity (FRC) (Wrigge et al. 1998). In large 
multicentre studies however, the use of this technology, with variation between 
manufacturers would be challenging. 
 Measuring biomarkers offers another possibility to recognize and stratify ALI 
patients better in future randomized trials. Large and heterogeneous patient 
populations provide more power for mortality prediction, but smaller, more 
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selected and homogeneous populations with more severe disease, and possibly 
greater treatment benefit, would be rational, especially in trials testing new therapies. 
Finding those patients who are most likely to benefit from potential therapy is 
essential. An example reflecting well on the significance of better stratification of 
patients in the studies is the finding that plasma RAGE associates with mortality 
only in patients with injurious tidal volumes (Calfee et al. 2008). Thus, the value of 
RAGE as a prognostic measure, seems poor in the present standard of care (lung 
protective ventilatory strategy). Of single biomarkers tested in large trials, none 
has proved to be excellent, and a combination of several biomarkers representing 
distinct aspects of the pathophysiology of ALI has been reported to be superior in 
mortality prediction (Ware et al. 2010). In addition to being potential tool in research, 
measurements of biomarkers could still provide a clinical tool for monitoring the 
course of disease or response to treatment. 
 An important future direction is to refine the criteria for ALI and ARDS. The 
AECC criteria, which have been established for almost 20 years, have not been able 
achieve what they were initially intended for. As noticed already more than decade 
ago, the use of these criteria in two concurrent studies resulted in two different 
kinds of ALI/ARDS patient populations, thus divergent results (Roupie et al. 1999, 
Villar et al. 1999). Additionally, the occurrence of ARDS has shown wide variation 
between centres even inside a single study, although the same criteria had been 
used (Brun-Buisson et al. 2004). Indeed, new criteria for ARDS have just been 
presented at the annual meeting of the European Society of Intensive Care Medicine 
(ESICM 2011, Berlin). ARF patients have a significant impact on healthcare, thus 
if the standard criteria for this condition could be defined, the research field would 
encompass a larger defined patient population.
 A well recognized existence of differences in the clinical picture of ALI, as well 
as in the susceptibility to develop ALI when exposed to risk factors, suggests a role 
for genetic variants. Studies of genetic polymorphisms have revealed several points 
in ALI pathogenesis, including ACE, IL-10, and TNF (Gong et al. 2006, Gong et al. 
2005, Marshall et al. 2002). Also, polymorphisms associated with genes regulating 
the coagulation cascade are potentially important in ALI, as has been characterized 
well earlier (Aiach et al. 1999, Arnaud et al. 2000, Endler et al. 2003). Studying the 
genetics of such a complex disease as ALI is challenging, in fact the genetic research 
of ALI remains in its infancy (Gao et al. 2009). A paucity of replication studies, 
which constitute to confirm the genotype-phenotype associations, is a common 
problem in the growing field of clinical genetic research in general and also with 
studies concerning ALI (Chanock et al. 2007). Genetic research of ALI is essential to 
fully understand the big picture of this syndrome, and will definitely be increasingly 
pursued in the future. 
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 Although much remains to be accomplished in future work, the studies of 
biomarkers has increased the knowledge of ALI pathophysiology enormously. 
A big dilemma remains, that smaller experimental studies, which can better 
measure the consequences of interventions and physiological incidents, often 
lack the power to show more than associations between matters. Furthermore, 
huge resources are needed to perform larger studies of reasonable study periods, 
with enough power for prognostic purposes, but also a patient population that 
is selected in a rational way.
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Conclusions
7 CONCLUSIONS 
Following conclusions can be drawn on the basis of these studies:
1. The calculated incidence of acute respiratory failure in Finnish ICUs was 149.5 
/ 100 000 inhabitants per year. The 90-day mortality was 31%. Tidal volumes 
were larger than recommended. In inspiratory pressures the recommendations 
were implemented better. 
2. Plasma NT-pro-BNP and cell-free DNA measured at baseline were commonly 
increased in ARF patients. Renal function and cardiac condition had impact on 
NT-pro-BNP values. Both NT-pro-BNP and plasma cell-free DNA at baseline 
were independent predictors for 90-day mortality. NT-pro-BNP and plasma 
DNA correlated with each other at baseline, and their use in combination may 
increase their prognostic value.
3.	The first week of ARF was represented by increased synthesis of collagen type 
III and degradation of collagen type I. Three weeks after ARF commenced, 
collagen metabolism reverted towards normal. No association with multiple 
organ dysfunction was noticed.
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